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Alzheimer’s disease (AD) is the most 
common form of dementia. The main 
symptoms of AD are decline in mem-
ory and cognition. Several candidate 
risk genes in AD have been identi-
fied but the exact molecular mecha-
nisms behind their effects are still 
unknown. This thesis looks at the 
genetic and functional contribution 
of specific risk genes to the patho-
genesis of AD. These studies further 
our knowledge and understanding of 
AD and may help identify potential 
targets for therapeutic interventions.
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ABSTRACT 
 
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the world. 
The main symptoms of AD are memory impairment and cognitive deterioration. 
Several candidate risk genes in AD have been identified but the exact molecular 
mechanisms behind their effects are still unknown. This thesis looks at the genetic and 
functional contribution of specific risk genes to the pathogenesis of AD.  
Mutations in the APP gene are known to cause AD. APP encodes the amyloid 
precursor protein (APP), which is processed to produce the amyloid beta (Aβ) peptide. 
Aβ peptides aggregate to form amyloid plaques in the brain parenchyma, one of the 
major neuropathological hallmarks of AD. Previous studies have reported duplications 
in the APP gene locus, leading to three copies of APP. The increased gene load 
invariably leads to early-onset of AD (EOAD). In study I, we screened Finnish EOAD 
patients for APP duplications. We found no duplications of the APP gene suggesting 
that APP duplications are rare in Finland.  
Mutations in the granulin (GRN) gene cause frontotemporal dementia (FTD). In 
study II, we wanted to assess the role of GRN in the susceptibility to AD. Our results 
indicated single nucleotide polymorphisms (SNPs) and haplotype that were over-
represented among male AD patients. These results suggest that GRN might play a role 
in AD susceptibility.  
In studies III and V, we investigated the effects of ubiquilin-1, which is both 
genetically and functionally associated with AD, on central molecular pathogenic 
events in AD in in vitro models. In study III, we assessed the role of ubiquilin-1 
transcripts variants (TVs) in presenilin 1 (PS1) aggregation. PS1 is the catalytic subunit 
of the γ-secretase enzyme complex which catalyses the production of Aβ. We found 
that ubiquilin-1 full-length TV1, and more prominently TV3 (which lacks exons 2, 3 and 
4), cause accumulation of full-length PS1 into aggresomes. Aggresomes are cytoplasmic 
inclusions containing aggregated ubiquitinated proteins. Aggresome formation was 
found to take place in neuronal but not glial cells. Electron microscopy showed that 
aggresomes were associated with autophagosomal structures suggesting clearance of 
aggresomes via autophagocytosis. We hypothesise that since TV3 lacks an essential 
VI 
 
domain that interacts with the proteasome, it is unable to mediate proteasomal 
degradation of PS1. This leads to PS1 accumulation into aggresomes, which are then 
gradually eliminated via autophagy.  
In study IV, we summarised our findings from study III along with a review of 
the current literature with respect to the role of ubiquilin-1 in protein aggregation and 
aggresome formation.   
Study V investigated the role of ubiquilin-1 TVs in APP processing and γ-
secretase function. At the molecular level, ubiquilin-1 is known to interact with PS1, 
although the functional consequences of this interaction are poorly understood. We 
report that TV1 increases APP maturation and processing and modulates PS-dependent 
γ-secretase activity, through independent mechanisms. TV2 which lacks exon 8, has 
been shown to be genetically associated with AD. We provide novel data showing that 
TV2 alters APP processing, but does not modulate γ-secretase activity in a similar 
manner as TV1. These differences could be the result of structural differences between 
the two TVs owing to alternative splicing.  
This thesis provides new genetic and functional information that relates to the 
effects of specific known and novel risk genes and their relationships in AD 
pathogenesis. These findings increase our understanding of the potential underlying 
molecular mechanisms involved in AD pathogenesis and may help in the 
indentification of novel therapeutic targets for treating AD. 
 
National Library of Medical Classification: WT155 
Medical Subject Headings: Senile dementia. Alzheimer's disease 
  
VII 
 
Viswanathan, Jayashree  
Genetic and functional characterisation of Alzheimer’s disease associated genes, 99 p.  
Itä-Suomen yliopisto, terveystieteiden tiedekunta, 2011 
Publications of the University of Eastern Finland. Dissertations in Health Sciences Number 62.  
 
ISBN: 978-952-61-0466-9  
ISBN: 978-952-61-0467-6 (PDF) 
ISSN: 1798-5706 
ISSN: 1798-5714 (PDF)  
ISSNL: 1798-5706 
 
TIIVISTELMÄ 
Alzheimerin tauti (AT) on yleisin dementiaa aiheuttava neurodegeneratiivinen sairaus, 
jonka kansanterveydellinen merkitys on huomattava. AT:n patogeneesin kannalta on 
keskeistä amyloidiprekursoriproteiinin (APP) pilkkoutumisessa tapahtuvat muutokset, 
jotka vaikuttavat amyloidi- (A) -peptidin tuontatoon ja kertymiseen aivokudoksessa. 
A-peptidin kertymisen tuloksena syntyneet amyloidiplakit ovatkin yhdessä 
neurofibrillivyyhtien kanssa AT:n neuropatologisia tunnusmerkkejä. AT:n geneettisten 
riskitekijöiden tunnistaminen on tärkeää etsittäessä keinoja sairauden 
ennaltaehkäisemiseksi. Riskigeenien geneettinen tunnistaminen ei kuitenkaan yksistään 
riitä selvittämään riskigeenimuutosten roolia AT:n patogeneesissä. Lisäksi tarvitaan 
toiminnallisia tutkimuksia, joissa riskigeenien vaikutusmekanismeja selvitetään taudin 
patogeneesin kannalta keskeisissä tapahtumissa solutasolla. Tässä väitöskirjatyössä 
keskityttiin AT:n uusien riskigeenien löytämiseen sekä jo aikaisemmin tunnistetun 
riskigeenin, ubikiliini-1:n, molekulaaristen mekanismien selvittämiseen solumalleissa. 
Lisäksi työssä tutkittiin APP-geenialueen duplikoitumista varhaisiän AT-potilailla.  
 Tutkimuksessa havaittiin, että APP-geenialueen duplikaatiota ei esiintynyt 
tutkituilla suomalaisilla varhaisiän AT-potilailla. Koska granuliinigeenin (GRN) 
mutaatioiden on osoitettu aiheuttavan ohimolohkodementiaa, tutkittiin GRN-geenin 
mahdollista roolia myös AT-potilailla. SNP-pohjainen assosiaatioanalyysi 
itäsuomalaisessa potilas-kontrolliaineistossa osoitti, että GRN-geenin 3’-pään SNP-
variaatiot (rs850713 ja rs5848) sekä niiden muodostama haplotyyppi lisäsivät miehillä 
merkittävästi riskiä sairastua Alzheimerin tautiin. 
 AT:n riskigeenin, ubikiliini-1:n, vaikutusmekanismeja tutkittiin preseniliini-1-
riippuvaisessa -sekretaasipilkkoutumisessa sekä proteiinikertymisessä erilaisissa 
solumalleissa. Preseniliini-1-proteiini (PS1) on osa -sekretaasikompleksia, joka pilkkoo 
APP:a. Ubikiliini-1-proteiinin osoitettiin lisäävän PS1:n proteiinitasoja sekä PS1:n 
kertymistä solunsisäisiin inkluusiokappaleisiin, aggresomeihin. Käyttäen fluoresenssin 
kestoon perustuvaa kuvantamista osoitettiin, että ubikiliini-1 sitoutuu PS1:een, mikä 
selittää niiden kulkeutumisen aggresomeihin. Lisäksi tutkimuksessa havaittiin, että 
aivoissa ilmentyvä ubikiliini-1:n varianttimuoto TV3 tehosti entisestään PS1:n 
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kertymistä aggresomeihin. Tämä puolestaan oli seurausta vähentyneestä ubikiliini-1-
välitteisestä PS1:n kuljetuksesta proteasomeihin hajotettavaksi. Ubikiliini-1 ja sen 
varianttimuoto eivät vaikuttaneet proteasomin yleiseen hajotusaktiivisuuteen tai 
ubikiliini-1:n ja PS1:n sitoutumiseen toisiinsa. Vaikka ubikiliini-1 ja sen varianttimuoto 
muokkasivat A:n tuotantoa, PS1:n kertyminen aggresomeihin ei vaikuttanut -
sekretaasin aktiivisuuteen tutkitussa ei-neuronaalisessa HEK293 solulinjassa.  
 Viimeisessä osatyössä keskityttiin ubikiliini-1-geenin transkriptivarianttien TV1 
and TV2 vaikutusmekanismien tutkimiseen APP:n pilkkoutumisessa sekä -sekretaasin 
toiminnassa SH-SY5Y-neuroblastomasolulinjassa. Transkriptivarianttien 
vaikutusmekanismien tutkiminen on tärkeää, sillä TV2:n lähetti-RNA tasojen tiedetään 
lisääntyvän AT-potilaiden aivoissa. Saatujen tulosten mukaan TV1 lisäsi sekä APP:n 
pilkkoutumista, että -sekretaasiaktiivisuutta, kun taas TV2 vaikutti ainoastaan APP:n 
pilkkoutumiseen SH-SY5Y-soluissa.   
 Yhteenvetona voidaan todeta, että APP:n geenialueen duplikaatioiden merkitys 
varhaisiän AT-potilailla on pieni, kun taas variaatiot GRN-geenin 3’-päässä voivat lisätä 
miehillä riskiä sairastua AT:iin. Lisäksi tutkimus osoitti, että ubikiliini-1-proteiinilla on 
merkittävä rooli AT:n kannalta keskeisten tekijöiden, kuten APP- ja PS1-proteiinien 
pilkkoutumisessa, kuljetuksessa, sekä kertymisessä. Edellä mainituissa muutoksissa 
havaittiin eroja neuronaalisten ja ei-neuronaalisten solujen välillä. Näin ollen geneettiset 
muutokset, jotka vaikuttavat ubikiliini-1-geenin toimintaan tai ilmentymiseen, voivat 
muokata AT:n riskiä.       
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SAMMANFATTNING 
Alzheimers sjukdom är den vanligaste formen av neurodegeneration. Sjukdomen 
drabbar oftast personer över 65 år med en incidens på cirka 50% bland individer över 85 
års ålder. Det vanligaste symptomet är närminnesstörning, men även språksvårigheter, 
desorientering och störd rumsuppfattning är vanliga problem. Dessa symptom är 
resultatet av en långsam successiv förlust av nervceller i de hjärnområden som ansvarar 
för minnen och andra kognitiva funktioner. 
Trots att Alzheimers sjukdom beskrevs redan för mer än 100 år sedan är de 
molekylära mekanismerna bakom nervcellsdöden fortfarande okända. Dock har 
moderna genetiska metoder gett oss viktig information gällande gener som orsakar, 
eller kan öka, risken för Alzheimers sjukdom. I denna avhandling har jag studerat några 
av dessa s.k. riskgener, samt vilka funktionella effekter dessa har på 
sjukdomsprocesserna.  
En av sjukdomsgenerna kodar för amyloid-prekursorproteinet (APP). Flera 
studier har rapporterat genduplikationer av APP hos patienter i bl a Frankrike och 
Holland. Dessa personer har tre i stället för två kopior av APP, vilket orsakar ett tidigt 
insjuknande genom den ökade produktionen av APP. I studie I har vi studerat 
förekomsten av APP duplikationer hos finska patienter med tidigt debuterande 
Alzheimers sjukdom (diagnos före 65 års ålder). Vi hittade dock inga APP 
duplikationer, viket tyder på att dessa är sällsynta i denna patientgrupp.  
Mutationer i genen för granulin (GRN) orsakar frontotemporal demens. I studie 
II ville vi undersöka om GRN även kan påverka risken för Alzheimers sjukdom. Med 
SNP (single nucleotide polymorphism)-baserad analys kunde vi påvisa att variationer i 
GRN genen ökar sjukdomsrisken, dock endast bland män. 
Studier III och V fokuserar på ubiquilin-1, en gen som tidigare visat sig vara 
genetiskt associerad till Alzheimers sjukdom. Vidare har man påvisat att ubiquilin-1 
påverkar processer i patogenesen, såsom APP spjälkning och bildning av amyloid-beta. 
I studie III har vi studerat effekten av olika polymorfa ubiquilin-1 transkript på 
aggregeringen av presenilin-1 (PS1). Vi kunde påvisa att ubiquilin-1 transkript-
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varianten TV1 (innehåller alla 11 exoner), men framför allt TV3 (saknar exoner 2, 3 och 
4), ökar aggregeringen av PS1 i s.k. aggresomer, cytoplasmiska aggregat av 
ubiquitinerade proteiner. Sådan aggresombildning visades ske i nervceller, men inte i 
gliaceller. Elektronmikroskopi påvisade att aggresomerna bryts ned av autofagocytos. 
Våra resultat indikerar att den ökade aggresombilningen uppstår genom att TV3 saknar 
en domän som behövs för interaktion med proteosomen, vilket resulterar i att PS1 kan 
börja aggregera och bilda aggresomer.   
 Artikel IV är en sammanfattning av våra resultat från studie III och andra 
aktuella studier som undersökt den roll ubiquilin-1 spelar för proteinaggregering och 
bildning av aggresomer. 
Studie V utreder hur ubiquilin-1 transkript-varianter påverkar spjälkningen av 
APP och funktionen hos γ-sekretas. Vi fann att TV1 påverkar dessa processer genom 
oberoende mekanismer. TV2, som saknar exon 8 och som visats vara genetiskt 
associerad till Alzheimers sjukdom, påverkar också spjälkningen av APP, men utan 
någon effekt på γ-sekretas. Dessa resultat tyder på att TV1 och TV2 har olika effekter på 
spjälkningen av APP och funktionen hos γ-sekretas. 
Sammanfattningsvis påvisar denna avhandling nya fynd kring de genetiska och 
molekylära mekanismerna bakom olika riskgener för Alzheimers sjukdom. Sådan ny 
kunskap är viktig för att i framtiden kunna utveckla nya terapier för sjukdomen. 
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1. Introduction 
 
Alzheimer’s disease (AD) is a common neurodegenerative disease that begins after the 
age of 65 years in the majority of cases (Brookmeyer R. et al., 1998). The main symptoms 
of AD include memory impairment, inability to form new memories and declining 
language and other cognitive skills (Waldemar G. et al., 2007). The prevalence of AD 
rises with age with up to 50% of individuals above the age of 85 suffering from this 
disease (Hebert L. E. et al., 2003). As more and more people survive into old age, 
treatment of geriatric diseases such as AD is becoming increasingly important, not only 
from a humanitarian point of view but also from an economic perspective. AD is the 
most common form of dementia accounting for 50-70% of dementia cases worldwide, 
and is estimated to cost an annual 172 billion USD in USA 
(http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf). In spite of the 
staggering statistics, there is still no cure for AD. Neither are the exact molecular 
mechanisms behind the cognitive decline known. However, genetic and environmental 
factors are known to play a role. Although mutations have been found in key genes 
affecting the disease pathogenesis, the majority of AD cases remain sporadic, i.e., 
lacking any known cause. 
 
The main and earliest symptoms of AD are memory and cognitive dysfunction, caused 
by a loss of neurons in the brain areas responsible for those functions (Waldemar G. et 
al., 2007). The two main neuropathological hallmarks of AD are the presence of 
aggregates of amyloid β (Aβ) in the brain parenchyma and paired helical filaments 
(PHFs) of hyperphosphorylated tau within axons. Both these protein aggregates are 
toxic to neurons and eventually cause neuronal death (Tiraboschi P. et al., 2004). Aβ is 
produced from amyloid precursor protein (APP) through a series of proteolytic 
cleavages mediated by α-, β- and γ-secretases (Selkoe D. J., 2001). Mutations in the APP 
gene have been found to cause AD with an earlier onset of disease compared to 
sporadic cases of AD. Also mutations in two other genes, namely PSEN1 and PSEN2 
genes which encode presenilin (PS) 1 and 2 respectively, are known to cause AD (Goate 
A. et al., 1991, Sherrington R. et al., 1995, Levy-Lahad E. et al., 1995a, Levy-Lahad E. et al., 
1995b, Rogaev E. I. et al., 1995). The PS proteins are catalytic components of γ-secretase, 
the enzyme which catalyses the production of Aβ (Tanzi R. E. et al., 2005). The two main 
forms of Aβ produced by γ-secretase cleavage are Aβ40 and Aβ42 consisting of 40 and 
42 amino acids respectively. PSEN1 and PSEN2 mutations favour production of the 
more aggregation prone Aβ42 protein, leading to an increase in the Aβ42/Aβ40 ratio. 
This leads to increased Aβ accumulation in the brain and consequently earlier onset of 
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the disease. There are also several genes that increase susceptibility to AD. The most 
prominent of these risk genes is APOEε4 which encodes apolipoprotein E (Corder E. H. 
et al., 1993, Saunders A. M. et al., 1993, Chartier-Harlin M. C. et al., 1994, van Duijn C. M. 
et al., 1994, Roses A. D., 1997). Apart from genes, environmental factors such as obesity, 
hypertension, cholesterol levels and education, also play an important role in the 
susceptibility to AD (Borenstein A. R. et al., 2005, Kivipelto M. et al., 2002, Refolo L. M. et 
al., 2000, Naderali E. K. et al., 2009, Schmand B. et al., 1997, Evans D. A. et al., 1997, 
Letenneur L. et al., 1999). 
 
The clearance and degradation of Aβ are as important as production of Aβ. It is 
believed that a chronic imbalance between these processes is the key in sporadic AD 
cases (Hardy J. et al., 1991). Aβ can be transported across the blood brain barrier (BBB) 
via receptors such as low-density lipoprotein receptor-related protein (LRP) and 
receptor for advanced glycation end products (RAGE; Wang Y. J. et al., 2006). Aβ can 
also be enzymatically degraded by enzymes, such as insulin degrading enzyme (IDE) 
and neprilysin (Miners J. S. et al., 2008).  
 
The second neuropathological hallmark of AD is the presence of PHFs of 
hyperphosphorylated tau in axons. Tau is a microtubule associated protein that helps 
maintain the cytoarchitectural integrity of neurons. The association of tau with 
microtubules is regulated by reversible phosphorylation of tau. However, perturbations 
in kinase or phosphatase activities lead to hyperphosphorylation of tau. The 
hyperphosphorylated tau molecules start to aggregate leading to PHF formation 
resulting in collapse of the cytoarchitecture of axons and neuronal death (Iqbal K. et al., 
2009, Takashima A., 2010, Maccioni R. B. et al., 2010).  
 
Protein aggregation is a common feature among several neurodegenerative diseases 
such as AD, Parkinson’s disease (PD), and Huntington’s disease (HD). In AD, the 
aggregation of Aβ and hyperphosphorylated tau plays an important role in the 
pathogenesis. However, recent findings indicate that oligomers of Aβ and tau, rather 
than the aggregates, might be the primary drivers of neuronal death (Naslund J. et al., 
2000, McLean C. A. et al., 1999, Lue L. F. et al., 1999, Maeda S. et al., 2007).  
 
There is yet another component to the pathogenesis of AD which is inflammation. The 
extracellular Aβ aggregates activate the innate immune system in the brain (McGeer P. 
L. et al., 1995, Rogers J. et al., 1996). As a result, microglia and astrocytes get activated. 
Activated microglia are found surrounding and phagocytosing plaques. It is believed 
that the inflammatory response rises as a result of Aβ plaques and is initially intended 
to limit the plaque burden in the brain. However, as the inflammation turns chronic, the 
inflammatory response itself contributes to neurotoxicity (Selkoe D. J., 2001).  
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AD is a complex disease consisting of multiple mechanisms. While genetic phenomena 
such as causative mutations in genes and gene duplications only explain a small 
fraction of the total number of AD cases, the majority lack any known cause. However, 
several risk genes have been identified that increase the susceptibility to AD and the list 
is constantly growing (Bertram L. et al., 2007). It is essential to elucidate the underlying 
molecular mechanisms behind the effects of the risk genes in order to increase our 
knowledge behind the disease pathogenesis of AD and to identify putative novel 
therapeutic targets against AD.  
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2. Review of the literature 
 
2.1 CLINICAL AND NEUROPATHOLOGICAL ASPECTS OF ALZHEIMER’S 
DISEASE 
 
AD is a neurodegenerative disease caused by a loss of neurons occurring over decades 
in a predestined pattern in the brain. The neurodegeneration starts in the entorhinal 
cortex and hippocampus, and progresses to the frontal and parietal neocortex. It is 
believed that the hippocampal neurodegeneration is correlated with early memory loss 
while the neocortical degeneration correlates with decline in other cognitive domains 
and personality changes at the more severe later stages of AD. This is because the 
hippocampus is an important centre for formation of episodic as well as declarative 
memory while the neocortex and frontal lobes are where conscious thoughts and 
reasoning originate (Squire L. R., 1992; Cohen, N. J. & Eichenbaum, H. 1993; Squire L. R. 
2002). Post mortem analysis of brains of diseased individuals reveals severe cortical 
atrophy and enlargement of the ventricles as a result of shrinkage of brain tissue (Wenk 
G. L., 2003).  
 
One of the most common diagnostic criteria for AD is based on the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-III-R and DSM-IV, American Psychiatric 
Association 1987 and 1995) and on the criteria of the National Institute of Neurological 
and Communicative Disorders and Stroke and Alzheimer’s Disease and Related 
Disorders Association Work Group (NINCDS-ADRDA; McKhann G. et al., 1984). 
According to the NINCDS-ADRDA criteria, AD is divided into three types. These are 
probable, possible and definite AD. The diagnosis for definite AD requires post-mortem 
analysis of brain tissue and presence of neuropathological hallmarks in the 
hippocampus, amygdala, and association cortices of the frontal, temporal, and parietal 
lobes according to the Neuropathology Task Force of the Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) criteria (Mirra S. S. et al., 1991). 
 
AD can be divided into three categories based on age at onset (Terry R. D. et al., 1983, 
Ertekin-Taner N., 2007). The most common form of AD is the sporadic or late-onset 
form (LOAD), accounting for approximately 90% of the AD cases and usually occurring 
after the age of 65 years. Statistics reveal that the risk for late-onset AD increases 
logarithmically with age, reaching a staggering 50% in people over the age of 85 years. 
Early-onset AD (EOAD) is a rare form of AD accounting for less than 10% of the total 
AD cases where individuals are diagnosed with AD before the age of 65. Individuals 
with Down’s syndrome (DS), who carry a trisomy at chromosome 21, often develop 
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dementia similar to AD by their 4th decade of life, and fall under this category. The third 
type is familial AD (FAD) where the disease is caused by fully penetrant causative 
mutations in specific genes. FAD is inherited in an autosomally dominant fashion and is 
very rare with less than 1% of the total AD cases being FAD.  
 
At the microscopic level, the neuropathology of AD reveals two hallmark lesions: 
plaques in the brain parenchyma containing aggregated Aβ protein and intra-axonal 
deposits of hyperphosphorylated microtubule-associated protein tau known as 
neurofibrillary tangles (Terry R. D. et al., 1983). Both plaques and neurofibrillary tangles 
are considered to be the leading causes of neurotoxicity (Selkoe D. J., 2001, Hardy J. et 
al., 1991, Selkoe D. J., 2000). Aβ is known to be synaptotoxic and synapses and axons in 
the vicinity of plaques have been known to degenerate (Selkoe D. J., 2001). 
Neurofibrillary tangles are directly toxic to axons and thereby cause the death of 
neurons (Selkoe D. J., 2002). During the early stages of the disease, there is a 25-30% loss 
in the synaptic density. As the disease progresses, synaptic loss correlates much more 
strongly with disease progression than plaques or neurofibrillary tangles (Selkoe D. J., 
2002, Terry R. D. et al., 1991). Accumulating evidence suggests that soluble Aβ 
oligomers cause changes in synaptic efficacy leading to deficits in spatial memory and 
long-term potentiation (LTP), both of which precede morphological alterations (Selkoe 
D. J., 2002, Larson J. et al., 1999, Moechars D. et al., 1999). The levels of Aβ and tau in the 
cerebrospinal fluid (CSF) are used as biomarkers for diagnosis of AD where the levels of 
Aβ42 are decreased and levels of total tau and phosphorylated tau are increased in AD 
patients compared to healthy controls (Blennow K. et al., 2010, Blennow K. et al., 2003). 
 
Another neuropathological lesion found in some AD cases is cerebral amyloid 
angiopathy (CAA). It is characterised by amyloid deposition in the cerebral vasculature 
leading to fibroid necrosis of the vessel wall and formation of microaneurysms. These 
predispose the vessels to rupture or leak, thus causing haemorrhage in the brain 
(Vasilevko V. et al., 2010). Individuals with FAD, DS and carriers of the ε4 allele of the 
APOE gene are associated with an increased Aβ deposition in the cerebral vasculature 
(Hamaguchi T. et al., 2008). Furthermore, polymorphisms in PSEN1 and NEP (encoding 
neprilysin), genes which are significant in the context of AD, have also shown 
association with CAA (Hamaguchi T. et al., 2008).  
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2.2 GENETICS OF ALZHEIMER’S DISEASE 
 
2.2.1 Causative gene mutations 
 
Although first described over a hundred years ago (Alzheimer A. et al., 1995 
[Translation of original text from 1907]), it took the onset of modern technology and 
genetics to enable a breakthrough in the discovery of causative gene mutations in AD. 
To date, mutations in APP, PSEN1 and PSEN2 are known to cause autosomal dominant 
form of AD (Goate A. et al., 1991, Sherrington R. et al., 1995, Levy-Lahad E. et al., 1995a, 
Levy-Lahad E. et al., 1995b, Rogaev E. I. et al., 1995). AD genetics research has since been 
inundated and the focus is now on the functional role of these known genes.  
 
APP is found on chromosome 21 and contains 240 kilobases encompassing 18 exons 
(Tanzi R. E. et al., 1987, Yoshikai S. et al., 1990, Lamb B. T. et al., 1993). Alternative 
splicing yields three isoforms namely APP695, APP751 and APP770 (Selkoe D. J., 2001). 
Homologous proteins have been found in other organisms such as mouse, rat, C. elegans 
and D. melanogaster (Jacobsen K. T. et al., 2009). So far, 32 critical mutations in the APP 
gene have been found that increase Aβ generation and lead to FAD 
(www.alzforum.org/res/com/mut/, www.molgen.ua.ac.be/ADMutations/). Mutations 
have been named by the region of origin, such as the Flemish, Dutch, Swedish and 
Arctic mutations (Figure 1). One of the more aggressive mutations is the Swedish 
mutation reported initially in 1992 by Selkoe and colleagues and found originally in a 
large Swedish pedigree (Citron M. et al., 1992). The mutation is a double mutation with 
substitutions of Lys to Asn at residue 670 and Met to Leu at position 671 
(K670N/M671L). Overexpression of APP containing this double mutation in cultured 
cells causes cells to secrete 6-8 fold more Aβ than cells overexpressing wild-type APP. 
This is due to increased cleavage by β-site APP cleaving enzyme 1 (BACE1; Citron M. et 
al., 1992). The K670N/M671L mutation was introduced into a mouse, the Tg2576 mouse 
model, first described by Ashe and colleagues (Hsiao K. et al., 1996). These animals 
present with extensive amyloid pathology and memory and learning impairment by 9 
months of age (Hsiao K. et al., 1996). Also, a conditional PS null mouse lacking both PS1 
and PS2 in the postnatal forebrain showed deficits in hippocampal memory and LTP, 
showing that PS proteins affect memory formation in the absence of Aβ (Saura C. A. et 
al., 2004). The Tg2576 mice were crossed with mice expressing PS1 with a deletion of 
exon 9 to produce the APP/PSΔ9 mice, which have since been a widely used model for 
AD. These mice present diffuse and dense-core amyloid plaques resembling senile 
plaques in human AD patients. The plaques are surrounded by activated microglia. 
However, these mice do not show neuronal loss or tau deposits (Hsiao K. et al., 1996, 
Games D. et al., 1995, Borchelt D. R. et al., 1997, Holcomb L. et al., 1998). In terms of 
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APP (Sleegers K. et al., 2006). This family also presented with CAA, demonstrating that 
CAA is a common feature of APP duplication. APP duplications have since been 
reported in EOAD families in Japan as well as UK (Kasuga K. et al., 2009, McNaughton 
D. et al., 2010). Interestingly, APP transcription can be increased by mutations in the 
APP promoter, resembling the APP duplication situation. Brouwers et al. reported three 
promoter mutations in a Belgian EOAD population that did not carry any APP 
duplications (Brouwers N. et al., 2006a). These mutations increased the promoter 
activity increasing transcription of APP gene. Furthermore, a study published in 2008 
showed how micro-RNAs (miRNAs) against APP could repress APP transcription and 
thus reduce APP levels in a cell culture model (Patel N. et al., 2008). The C. elegans 
orthologue of APP, APL-1 has also been shown to be regulated by miRNA during 
development (Niwa R. et al., 2008). Therefore, levels of APP can be modulated through 
various mechanisms.  
 
The remaining two genes having causative mutations in AD are the PSEN1 and PSEN2 
genes coding for PS1 and 2 respectively. PS1 and PS2 are critical members of the γ-
secretase, the enzyme cleaving APP to produce Aβ (Tanzi R. E. et al., 2005). PSEN1 is 
located on chromosome 14 and PSEN2 on chromosome 1. While mutations in APP gene 
increase Aβ generation in general, the PSEN mutations specifically increase Aβ42, the 
more toxic and aggregation-prone variant of Aβ. FAD caused by PSEN1 mutations are 
the most aggressive forms of AD with onset age as young as 30 years (Vetrivel K. S. et 
al., 2006). So far 182 mutations in PSEN1 and 14 mutations in PSEN2 have been reported 
and the list is constantly being updated (www.molgen.ua.ac.be/ADMutations/). 
 
2.2.2 Risk genes 
 
In the past, genetic linkage studies followed by candidate gene approaches and 
positional cloning have been successful in identifying the three causative genes in 
EOAD (Ertekin-Taner N., 2007). Candidate gene approaches use an “educated guess” 
approach to find alleles in genes that may be involved in disease progression and that 
are over- or under-represented in patients (Kwon J. M. et al., 2000). Linkage study, 
followed by positional cloning is the process of systematically mapping the genome of 
members of affected families using highly variable polymorphic DNA segments whose 
exact position is known (Kwon J. M. et al., 2000). The latter is advantageous in cases 
where researchers have no prior knowledge of the biology underlying the disease, or 
when studying complex diseases such as AD where there can be several underlying 
causes (Kwon J. M. et al., 2000). In case of LOAD, the finding of APOE as one of the 
most persistent susceptibility genes with the highest risk effect, has been the most 
significant contribution (Corder E. H. et al., 1993, Saunders A. M. et al., 1993, Chartier-
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Harlin M. C. et al., 1994, van Duijn C. M. et al., 1994, Roses A. D., 1997). Furthermore, 
studies of familial aggregation of AD, transmission pattern studies and twin studies 
have increased our knowledge of the disease tremendously. However, results from 
these approaches have led to the conclusion that there is a vast genetic component to 
AD beyond that of the known causative gene mutations and susceptibility genes 
mentioned above (Ertekin-Taner N., 2007). With the dawn of the new millennium, high-
tech high-throughput techniques using robotics to generate vast amounts of genotyping 
data using microsatellites and single nucleotide polymorphisms (SNPs) at lower cost 
than before, have ushered in a new era of whole genome linkage association studies to 
increase our understanding of the contribution of genetics to LOAD.  
 
Genome-wide association studies (GWAS) in AD in case-control and longitudinal 
cohorts have generated valuable data. GWAS is an examination of the entire genome of 
individuals using thousands of SNPs to see how much variation there is between 
patients and controls. A collaborative study between USA and the Netherlands 
conducted on a neuropathologically confirmed AD cohort revealed a SNP on 
chromosome 19 in linkage disequilibrium (LD) with APOEε4 (Coon K. D. et al., 2007). 
LD is defined as the non-random association of alleles at two loci, i.e., when an allele at 
one locus is found together with an allele at another locus more often than expected 
assuming the loci were segregating independently. The loci that are in LD are said to 
belong to a haplotype where the SNPs are inherited together. The study confirmed the 
finding of APOE as a major susceptibility gene. A second study published the same year 
stratified their LOAD cohort in APOEε4 carriers and non-carriers. The authors found a 
SNP on GAB2 gene on chromosome 11q14.1 that significantly increased risk of AD 
among APOEε4 carriers (Reiman E. M. et al., 2007). A study published by Grupe et al. 
was the first study with a large sample set of 1808 LOAD patients and 2062 control 
samples (Grupe A. et al., 2007). They revealed 19 markers that significantly increased 
risk of AD. Three of the 19 SNPs were in LD with APOE which confers validity to these 
results. Authors also found three SNPs in genes that were relevant to AD, namely 
galanine-like peptide precursor (GALP) on chromosome 19q13.42, nonreceptor tyrosine 
kinase (TNK1) on chromosome 17p13.1, and phosphoenolpyruvate carboxykinase 
(PCK1) on chromosome 20q13.31 (Grupe A. et al., 2007). A fourth relevant study was 
conducted in a genetically isolated cohort from the Netherlands and confirmed the 
previous linkage of 1q25, 10q22-24, and 11q25 associated with AD (Liu F. et al., 2007).  
 
One of the largest GWAS studies conducted using samples pooled from Belgium, 
France, Finland and Italy, totaling the AD samples to 3978 cases with 3297 control 
samples, revealed two loci that significantly associated with increased risk of AD. One 
lay within CLU encoding clusterin or apolipoprotein J (APOJ) on chromosome 8, and 
the second within CR1 encoding the complement component (3b/4b) receptor 1 on 
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chromosome 1 (Lambert J. C. et al., 2009). Aβ complexed with APOJ is transported from 
the periphery to the brain across the BBB via gp330/megalin (Zlokovic B. V. et al., 1996, 
Zlokovic B. V., 2004). This makes the finding by Lambert et al. also functionally relevant. 
Since inflammation and the complement systems are also activated in AD pathogenesis 
(Selkoe D. J., 2001, Terry R. D. et al., 1983), CR1 association is also an interesting finding. 
Recently, two new studies have been published based on an even larger cohort (>6000 
patient and >13000 control samples) reporting associations with novel genes namely 
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP (Hollingworth P. et al., 2011, Naj 
A. C. et al., 2011).  
 
In an effort to incorporate the ever growing list of new candidate genes, a database was 
created at www.alzforum.org (Bertram L. et al., 2007) with a meta-analysis of all the 
published genetic findings in the field, and the list is constantly being updated (Table 
1). The number 1 candidate gene on that list is APOE and it has remained unchallenged 
ever since its discovery. APOEε4 vs. ε3 has an odds ratio of 3.68 implying that 
heterozygous carriers of the ε4 allele are 3.68 times more likely to develop AD than non 
carriers. So far, no other risk gene has been able to show such a strong risk effect. The 
other genes in order of decreasing association, and the proteins the genes encode, are 
shown in Table 1 (based on reports published by April 2011). 
 
Table 1. List of the current top 10 risk genes in AD. 
 
 Gene Chromosomal 
location 
Odds ratio  
(95% CI)* 
Protein 
1. APOE 19q13.32 3.68 (3.30, 4.11) Apolipoprotein 
2. BIN1 2q14.3 1.15 (1.10, 1.20) Bridging integrator 1 
3. CLU 8p21.1 0.88 (0.86, 0.91) Clusterin 
4. ABCA7 19p13.3 1.23 (1.18, 1.28) ATP-binding cassette, subfamily A, 
member 7 
5. CR1 1q32.1 1.14 (1.08, 1.20) Complement component (3b/4b) 
receptor 1 (Knops blood group)  
6. PICALM 11q14.2 0.88 (0.85, 0.91) Phosphatidylinositol-binding clathrin 
assembly protein 
7. MS4A6A 11q12.2 0.9 (0.88, 0.93) Membrane-spanning 4-domains, 
subfamily A, member 6A 
8. CD33 19q13.33 0.89 (0.86, 0.92) CD33 
9. MS4A4E 11q12.2 1.08 (1.05, 1.11) Membrane-spanning 4-domains, 
subfamily A, member 4E 
10. CD2AP 16p12.3 1.12 (1.08, 1.16) CD2-associated protein 
 
*Odds ratio is calculated from all studies including the initial study. 
(Bertram L, McQueen M, Mullin K, Blacker D, Tanzi R. The AlzGene Database. Alzheimer Research 
Forum. Available at: http://www.alzgene.org. Accessed 2011.04.10). 
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Based on the top gene list on www.alzforum.org, Sarajärvi et al. chose the top 21 gene 
polymorphisms and genotyped an isolated Finnish cohort consisting of a total of 1300 
samples (Sarajarvi T. et al., 2010). They found a significant association between a SNP in 
the tumour necrosis factor-α (TNFα) gene and AD, revealing a protective effect of the 
minor allele. Since TNFα plays a part in the inflammatory process (Feuerstein G. Z. et 
al., 1994), this finding suggests that perhaps certain alleles protect against AD by 
modulating the inflammatory response. Recently, BIN1 and PICALM variations were 
also shown to play a role among the Finnish case-control cohort (Lambert J. C. et al., 
2011).  
 
It has become clear that the population sizes of cohorts when screening for risk genes 
need to be very large in order to detect very low penetrant and low risk effect genes. For 
this reason, pooling of populations from several cohorts in international collaborations 
has proven successful. However, it is important to mention that this approach has 
disadvantages. Pooling populations of different origins could mask rare gene variants 
which are specific for those populations.  
 
Once risk genes have been identified in AD, the next step is to elucidate the epigenetics 
behind the genes and characterise the underlying functional and molecular mechanisms 
behind the actions of these genes. One way is to modulate levels of the protein products 
of these genes in model systems and study the effects on the key pathogenic cascades in 
AD, such as altered APP processing and Aβ production.  
 
2.3 ENVIRONMENTAL RISK FACTORS OF ALZHEIMER’S DISEASE 
 
Apart from the genetic component, a multitude of environmental factors are also 
associated with increased risk of AD. An increased risk of dementia and AD in less 
educated individuals has been reported by many studies (Schmand B. et al., 1997, Evans 
D. A. et al., 1997, Letenneur L. et al., 1999). Furthermore, increased mental activity has 
been proposed to provide beneficial influence on cognition by increasing synaptic 
density (van Praag H. et al., 2000). An interesting study published by Lazarov et al. 
demonstrated that APP/PSΔ9 mice that were raised in an “enriched environment”, a 
paradigm used to mimic increased mental activity, showed reduced Aβ pathology 
compared to mice raised in “standard environment”. Furthermore, the mice that were 
more physically active showed the most significant reductions in Aβ pathology 
(Lazarov O. et al., 2005b). Those mice were also shown to have improved cognition by a 
study published shortly after (Jankowsky J. L. et al., 2005). These studies show that 
increased environmental stimuli can modulate cerebral accumulation of Aβ. 
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The risk for AD is higher among women compared to men (Bachman D. L. et al., 1992, 
Bachman D. L. et al., 1993, Tang M. X. et al., 1996, Henderson V. W. et al., 1994, McEwen 
B. S., 1991). This has been attributed to two main reasons. Firstly, women have longer 
life spans than men. Secondly, as women age and undergo menopause, the levels of 
oestrogen reduce. Oestrogen has been shown to have neuroprotective effects and it is 
believed that this drop in oestrogen levels leads to reduced neuroprotection, and hence 
neurological and cognitive decline (Bachman D. L. et al., 1992, Bachman D. L. et al., 1993, 
Tang M. X. et al., 1996, Henderson V. W. et al., 1994, McEwen B. S., 1991).  
 
Obesity and diabetes along with hyperlipidemia and hypertension are dietary factors 
that have shown association with AD (Borenstein A. R. et al., 2005, Kivipelto M. et al., 
2002, Refolo L. M. et al., 2000, Naderali E. K. et al., 2009). It is possible that chronic 
increase in glucose levels as a result of diabetes results in abnormalities in cerebral 
capillaries, possibly leading to an increased risk for ischaemia and dementia (Gispen W. 
H. et al., 2000, Biessels G. J. et al., 2002). Glucose itself can also be a driver of 
neurodegeneration as shown by Biessels et al. They showed that hyperglycaemic rats 
displayed cognitive decline and abnormalities in synaptic plasticity (Biessels G. J. et al., 
1996). Finally, insulin in the brain competes with Aβ for IDE, one of the main enzyme 
degrading Aβ (Watson G. S. et al., 2003). It is possible that in diabetic patients, 
hyperinsulinemia leads to reduced degradation of Aβ leading to increased risk of AD 
(Watson G. S. et al., 2003). A recent study conducted in a Finnish dementia-free elderly 
cohort has revealed that also homocysteine and holotranscobalamin, the active fraction 
of vitamin B12, are associated with increased risk of AD (Hooshmand B. et al., 2010).  
 
2.4 MOLECULAR MECHANISMS UNDERLYING ALZHEIMER’S DISEASE 
PATHOGENESIS 
 
2.4.1 APP processing and Aβ production 
 
APP, as the name suggests, is the precursor of Aβ. APP is a type-I transmembrane 
protein with a large N-terminal ectodomain and a short C-terminal intracellular tail. It 
belongs to the larger family of proteins known as APP-like proteins (APLPs). APP is a 
ubiquitously expressed protein which has been suggested to play a role in neuronal 
migration, synapse formation, neurite extension, cell adhesion and protein transport 
(Masliah E. et al., 1997, Priller C. et al., 2006, Lazarov O. et al., 2005a, LeBlanc A. C. et al., 
1992, Coulson E. J. et al., 1997, Soba P. et al., 2005, Hoe H. S. et al., 2009). APP is 
alternatively spliced to produce mainly 3 isoforms, APP695, APP751 and APP770 
(Selkoe D. J., 2001, Tanzi R. E. et al., 2005). APP also undergoes post-translational 
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modifications such as N- and O-glycosylation, sulfation and phosphorylation. The 
APP751 and 770 isoforms are widely expressed in non-neuronal cells, while APP695 is 
expressed almost exclusively in neurons. It is thought that one of the reasons for the 
higher expression of the longer APP isoforms 751 and 770 in non-neuronal cells might 
be the result of the presence of the Kunitz-type inhibitor (KPI) domain. This domain is a 
serine protease inhibitor and has been shown to affect the processing of APP (Ho L. et 
al., 1996). After translation, APP is trafficked from the endoplasmic reticulum (ER) 
through the secretory pathway to the cell surface. During trafficking, APP undergoes N- 
and O-glycosylation, phosphorylation and tyrosine sulfation. APP reaching the trans-
Golgi network (TGN) and plasma membrane is known as mature APP and is primarily 
processed by the α-secretase (Selkoe D. J., 2001). However, a large proportion (~70%) of 
APP is endocytosed within minutes of arriving to the plasma membrane. This is 
mediated by the APP C-terminal “YENPTY” internalisation motif. Once endocytosed, a 
fraction of the APP molecules is recycled to the plasma membrane while the majority is 
delivered to the endosomes or degraded by lysosomes.  
 
The production of Aβ from its precursor requires sequential enzymatic processing 
(Figure 1; Chow V. W. et al., 2010, Yamada K. et al., 2002). APP can be processed 
through two alternative pathways (Figure 2). Approximately 10% of APP is processed 
through the amyloidogenic pathway, which results in the production of Aβ. This 
processing might be increased in neurons compared to non-neuronal cells (Vetrivel K. 
S. et al., 2006). The remaining 90% is processed through the non-amyloidogenic pathway 
which excludes Aβ production. In the amyloidogenic pathway, APP is first cleaved at 
its N-terminus by β-secretase resulting in ectodomain shedding and release of secreted 
APP β (sAPPβ), leaving a 99-amino acid (aa) C-terminal fragment (CTF) C99 embedded 
in the plasma membrane. sAPPβ or a further fragment generated from it, has been 
shown to cause degeneration of axons of developing peripheral neurons in a caspase-
dependent manner by binding to death receptor 6 (Nikolaev A. et al., 2009). C99 further 
acts as a substrate for γ-secretase which produces Aβ and the APP intracellular domain 
(AICD). Alternatively, APP N-terminus can be cleaved by α-secretase in the non-
amyloidogenic pathway, releasing secreted APPα (sAPPα) and yielding a membrane-
bound C83 CTF. The sAPPα is reported to have effects on signalling and neuronal 
plasticity and is generally considered to be neuroprotective (Furukawa K. et al., 1996, 
Hiltunen M. et al., 2009). sAPPα has also been shown to be highly potent in protecting 
hippocampal neurons against excitotoxicity, Aβ toxicity and glucose deprivation 
(Furukawa K. et al., 1996, Araki W. et al., 1991, Mattson M. P. et al., 1993, Schubert D. et 
al., 1993, Jin L. W. et al., 1994, Roch J. M. et al., 1994, Smith-Swintosky V. L. et al., 1994, 
Goodman Y. et al., 1994). C83 also acts as a substrate for γ-secretase which releases the 
p3 fragment and AICD (Selkoe D. J., 2001). C99 may also act as a substrate for the α-
secretase which cleaves excess C99 to produce C83. The majority of the non-
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amyloidogenic processing of APP by the α-secretase takes place close to or at the 
plasma membrane (Vetrivel K. S. et al., 2006). APP which is endocytosed is processed by 
β-secretase, which resides in the Golgi and endosomes where the mildly acidic 
environment is optimal for β-secretase function. The γ-secretase has been shown to be 
active in multiple compartments including the ER, Golgi, endosomes and the plasma 
membrane. The γ-secretase cleavage releasing the Aβ fragment mainly occurs in the 
TGN and endosomes (Vetrivel K. S. et al., 2006).  
 
 
 
Figure 2. Schematic representation of the processing of APP through the non-amyloidogenic 
(left) and the amyloidogenic (right) pathways. The non-amyloidogenic pathway starts with 
cleavage of APP by the α-secretase releasing sAPPα and yielding C83. The amyloidogenic 
pathway is initiated by cleavage of APP by the β-secretase releasing sAPPβ and generating 
C99. Both C83 and C99 are cleaved by γ-secretase to release p3 and Aβ, respectively. Aβ 
aggregates into oligomeric species which have been shown to impair LTP. The oligomers 
aggregate to form Aβ plaques which cause inflammation and ultimately neuronal death. 
AICD is released via both the non-amyloidogenic and the amyloidogenic pathways. AICD 
has been shown in vitro to localise to the nucleus and form a ternary complex along with 
Tip60 and FE65 (known as AFT complex) and activate transcription of genes such as Aβ-
degrading enzyme neprilysin and the tau-phosphorylating kinase GSK3β. 
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The AICD fragment has been shown to play a role in gene transcription. This function is 
suggested especially for the AICD which is produced via the amyloidogenic pathway 
(Goodger Z. V. et al., 2009). AICD has a short half-life and is rapidly degraded by 
enzymes such as IDE (Cupers P. et al., 2001, Edbauer D. et al., 2002). The “YENPTY” 
motif in AICD, which is important for internalisation of APP, can interact with adaptor 
proteins that possess a phosphotyrosine binding domain (PTB). These proteins include 
the FE65, FE65L, FE65L2, X11/Mint, mammalian disabled 1 (mDab1), Numb, 
engulfment adaptor protein 1 (GULP1) and JNK-interacting protein 1 (JIP) family of 
adaptor proteins (Fiore F. et al., 1995, Guenette S. Y. et al., 1996, Duilio A. et al., 1998, 
Borg J. P. et al., 1998, Trommsdorff M. et al., 1998, Roncarati R. et al., 2002, Hao C. Y. et 
al., 2011, Matsuda S. et al., 2001). FE65, FE65L1 and FE65L2 belong to the FE65 
adaptor/scaffolding protein family. All three contain two PTB domains through which 
they can interact with AICD (McLoughlin D. M. et al., 2008). Binding of FE65 to AICD 
has been shown to stabilise AICD, and suggested to mediate its translocation to the 
nucleus (Kimberly W. T. et al., 2001, Cao X. et al., 2001). Once in the nucleus, AICD and 
FE65 bind the histone acetyltransferase Tip60 to form a trimeric complex consisting of 
AICD-FE65-Tip60 (also known as AFT complex, Figure 2) which has been reported to 
mediate transcriptional regulation of APP, BACE, Tip60, GSK3β and KAI1 genes 
(Konietzko U. et al., 2010, von Rotz R. C. et al., 2004). However, AICD function in 
transcription has recently been challenged by studies using γ-secretase inhibitors and γ-
secretase- or APP-deficient models (Hebert S. S. et al., 2006, Waldron E. et al., 2008).  
These studies suggested that AICD may not be directly required for the transcriptional 
regulation of its suggested target genes and that its interaction with Fe65 may not lead 
to nuclear translocation. 
 
2.4.2 α-, β- and γ-secretases 
 
The α-secretase is a zinc metalloproteinase. Members belonging to the family of a 
disintegrin and metalloproteinase (ADAM) such as ADAM10, ADAM17 (tumour 
necrosis factor-α converting enzyme [TACE]) and ADAM9 and have been found to 
demonstrate α-secretase activity (Marks N. et al., 2008). α-secretase is membrane bound 
and found predominantly on the plasma membrane (De Strooper B. et al., 2010).  
 
The major neuronal β-secretase, BACE1, is a transmembrane aspartic-acid protease (De 
Strooper B. et al., 2010, Willem M. et al., 2009). BACE1 cleaves APP to generate the N-
terminus of Aβ, however it is believed that APP is not the sole physiological substrate 
for BACE1 (Willem M. et al., 2009). BACE1 undergoes extensive post-translational 
modifications including phosphorylation, N-glycosylation and pro-peptide cleavage 
(De Strooper B. et al., 2010, Willem M. et al., 2009). The second isoform of BACE, BACE2, 
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shares ~75% homology with BACE1 (Bennett B. D. et al., 2000, Sun X. et al., 2005). While 
both BACE1 and BACE2 can cleave APP, BACE1 has a much higher preference for APP 
(Farzan M. et al., 2000, Hussain I. et al., 2000). For this reason, BACE1 is believed to be 
the principal β-secretase in the brain responsible for Aβ production, while the role of 
BACE2 is not yet fully understood.  
 
The third secretase, the γ-secretase, is an enzymatic complex consisting of four 
components namely PS1 or PS2, presenilin enhancer 2 (PEN-2), anterior pharynx 1 
(APH-1) and nicastrin (NCT; Kaether C. et al., 2006a; Figure 3). PS1 and PS2 are crucial 
components of the γ-secretase as they contain the catalytic aspartyl residues in 
transmembrane domain (TMD) 6 and 7 (Sato C. et al., 2006). APH-1 was originally 
found as a regulator of cell-surface localisation of NCT and acts as a scaffold for 
complex formation (Goutte C. et al., 2002). NCT was initially suggested to act as a 
receptor for substrates in the γ-secretase complex, but this function was recently refuted 
(Shah S. et al., 2005, Chavez-Gutierrez L. et al., 2008, Zhao G. et al., 2010). PEN-2-/- 
embryos show severe Notch1 deficiency phenotype (Bammens L. et al., 2011). Notch1 
null mice are non-viable and do not survive after 11.5 days of gestation. In the 
neurogenic regions in Notch1 null mice, all the cells become neuroblasts causing vast 
hypertrophy of the nervous system leading to death. There is also a corresponding lack 
of epidermal structures (Conlon R. A. et al., 1995, Swiatek P. J. et al., 1994). This suggests 
that PEN-2 not only contributes to the structural stability of the γ-secretase but also to 
the proper catalytic functioning of the γ-secretase (Bammens L. et al., 2011).  
 
PSs are synthesised as holoproteins of approximately 50 kDa which are rapidly 
endoproteolysed through autoproteolysis to generate the PS-NTF (~30 kDa) and PS-CTF 
(~20 kDa) that remain noncovalently bound together (Wolfe M. S. et al., 1999). As a 
result, the CTF and NTF forms of PS are the dominant forms present in cells 
(Thinakaran G. et al., 1996, Ratovitski T. et al., 1997, Thinakaran G. et al., 1997). The 
proposed γ-secretase assembly starts with APH-1 and NCT forming a stable complex. 
This is followed by the addition of the PS holoprotein to the complex. PEN-2 is the last 
member to be inserted into the complex and the entry of PEN-2 promotes the 
endoproteolysis of PS holoprotein at the large cytoplasmic domain between TMDs 6 
and 7 (as reviewed in Periz G. et al., 2004).  
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2.4.3 Aβ degradation 
 
While in FAD an increase in Aβ generation is the cause of AD onset, this is rarely 
observed in sporadic cases. In the latter cases, reduced clearance of Aβ plays an equally 
important role as the generation and accumulation of Aβ. A chronic imbalance between 
these processes is a key factor in sporadic AD (Hardy J. et al., 1991). Several candidate 
enzymes have been proposed to have Aβ-degrading properties, the most common 
being neprilysin, IDE, angiotensin-converting enzyme (ACE), endothelin-converting 
enzyme (ECE), plasmin, tissue-type plasminogen activator (tPA) and urokinase-type 
plasminogen activator (uPA; Miners J. S. et al., 2008). Neprilysin is an important Aβ-
degrading enzyme (Miners J. S. et al., 2008). It is a type-II membrane protein where the 
active site protrudes into the extracellular space where Aβ is released. Neprilysin has 
metalloendopeptidase activity and its active site contains a zinc-binding motif. 
Neprilysin usually degrades peptides smaller than 5 kDa in size, however, it has been 
suggested to also degrade oligomers of Aβ (Miners J. S. et al., 2008). Neprilysin 
overexpression in primary cortical neurons led to a decrease in secreted and membrane-
associated Aβ (Hama E. et al., 2001). The levels of neprilysin were reduced in the brains 
of aging mice but this was proven not to result from neuronal or synaptic loss. Rather, it 
appears that neprilysin is downregulated in aging brains and this is associated with 
increased accumulation of Aβ (Iwata N. et al., 2002). Another important Aβ-degrading 
enzyme is IDE. As the name suggests, the primary substrate of IDE is insulin for which 
it has the highest affinity. However IDE has the second highest affinity for Aβ and as 
opposed to neprilysin, IDE can degrade only Aβ monomers (Qiu W. Q. et al., 1998). A 
post-mortem study concluded that protein and mRNA levels of IDE were reduced in 
hippocampi of individuals suffering from AD with the APOEε4 allele (Cook D. G. et al., 
2003). It has also been shown in a human study by Watson et al. that insulin infusion 
leads to an increase in CSF Aβ levels indicating the possibility that insulin competes 
with Aβ for IDE (Watson G. S. et al., 2003).  
 
Apart from direct degradation by enzymes, APP can also be degraded by the 
proteasome and ER-associated pathways (Chen Q. et al., 2002, Hare J. F., 2006, Bunnell 
W. L. et al., 1998). APP has been shown to be a substrate for the ER-associated 
degradation (ERAD) pathway (Huttunen H. J. et al., 2007). The authors found that 
HtrA2, an APP-interacting chaperone protease, mediates APP degradation by the 
proteasome via ERAD. In this way, HtrA2 regulates cellular levels of APP.  
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2.4.4 Aβ clearance 
 
The interstitial fluid levels of Aβ are maintained through several processes. One of these 
is degradation through Aβ-degrading enzymes as discussed above. Another process is 
the receptor-mediated influx and efflux of Aβ through the BBB between the brain and 
the periphery. This exchange is receptor-mediated because Aβ is a polar solute and 
cannot cross the endothelial cell membrane lining of the blood vessels (Begley D. J. et al., 
2003). Efflux of Aβ from the brain to the periphery is mediated by two known 
mechanisms (as reviewed by Wang Y. J. et al., 2006). The first mechanism is through 
LRP1. LRP1 is a lipoprotein receptor expressed on the capillary endothelium that binds 
a broad range of secreted proteins such as α-2 macroglobulin, APP, Aβ, APOE etc. and 
mediates their transcytosis into the blood vessel lumen (Herz J. et al., 2003). LRP1 is 
genetically associated with AD and also affects APP processing and metabolism 
(Zerbinatti C. V. et al., 2004). Also, complexes of Aβ bound to α-2 macroglobulin or 
APOE can be endocytosed by LRP (Narita M. et al., 1997). The second efflux mechanism 
involves ATP-binding cassette transporter p-glycoprotein, which acts an efflux pump 
for Aβ at the BBB (Lam F. C. et al., 2001).  
 
Influx from the periphery into the brain also involves two known receptors. The first is 
RAGE. RAGE belongs to the immunoglobulin family and like LRP is a multiligand 
receptor (Deane R. et al., 2004). RAGE is implicated in the regulation of neurite 
outgrowth and cell migration (Huttunen H. J. et al., 2002, Srikrishna G. et al., 2002). Also, 
RAGE has been implicated in AD by mediating influx of Aβ from the periphery into the 
brain at pathophysiologically relevant concentrations (Deane R. et al., 2003, Mackic J. B. 
et al., 1998). The influxed Aβ is rapidly taken up by neurons increasing neuronal stress 
and neurodegeneration (Deane R. et al., 2003). Interestingly, while increased brain Aβ 
levels lead to downregulation of LRP in a negative feedback loop, the opposite seems to 
be the case for RAGE. RAGE expression is sustained at high levels as the result of a 
positive feedback loop in response to high Aβ brain levels (Shibata M. et al., 2000). In 
this way, RAGE can exacerbate the disease progression even further. Another protein 
that has been reported to transport Aβ from the peripheral blood supply back to the 
brain is gp330/megalin. Gp330/megalin transports Aβ complexed with APOJ across the 
BBB. However, most of the gp330/megalin is saturated with APOJ making its 
contribution to Aβ influx into the brain minimal compared to that of RAGE (Zlokovic B. 
V. et al., 1996, Zlokovic B. V., 2004).  
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2.4.5 Tau hyperphosphorylation 
 
The second neuropathological hallmark of AD is neurofibrillary tangle formation. 
Neurofibrillary tangles are intracellular deposits of PHFs consisting of 
hyperphosphorylated tau proteins (Iqbal K. et al., 2009, Takashima A., 2010, Maccioni R. 
B. et al., 2010). While amyloid plaque load does not seem to have an obvious correlation 
with AD severity, there is a close correlation between the amount of PHFs and 
progression of dementia in AD. Also, the CSF levels of tau are increased in AD patients. 
These levels correlate very well with AD severity and progression (Hock C. et al., 1995, 
Jensen M. et al., 1995, Mori H. et al., 1995, Vandermeeren M. et al., 1993, Vigo-Pelfrey C. 
et al., 1995). Tau is transcribed from the MAPT gene on chromosome 17q21, and 
alternative splicing produces six isoforms of tau. Tau is a microtubule-associated 
protein (MAP) which interacts with tubulin to stabilise microtubules in the cell. This 
leads to stabilisation of the cytoskeleton of the cell (Iqbal K. et al., 2009). Stable 
microtubules are also structures upon which organelles, growth factors etc. are 
trafficked within the cell (Hernandez F. et al., 2007). The interaction of tau with 
microtubules is regulated by tau phosphorylation by kinases. Tau phosphorylation 
leads to its dissociation from microtubules leading to microtubule instability (Taniguchi 
T. et al., 2001). In humans, tau is mostly present in neurons where its function is to 
stabilise axons. Hyperphosphorylated tau is found scattered in the neuropil in the grey 
matter (Iqbal K. et al., 2009). Tau hyperphosphorylation has been suggested to result 
from aberrant phosphorylation by kinases or disturbed function of phosphatases 
(Hernandez F. et al., 2007). Post mortem studies conducted on human AD brains 
showed that protein phosphatase 2 A and 2 B (PP2A, PP2B) might be downregulated in 
AD brains leading to increased levels of phosphorylated tau (Goedert M. et al., 1992). 
Several kinases have been shown to phosphorylate tau. These include mitogen activated 
protein kinase (MAPK), glycogen synthase kinase 3 (GSK3), and cyclin-dependent 
kinases (CDK) 2 and 5, among others (Drewes G. et al., 1992, Hyman B. T. et al., 1994, 
Ledesma M. D. et al., 1992, Trojanowski J. Q. et al., 1993, Hanger D. P. et al., 1992, 
Ishiguro K. et al., 1993, Mandelkow E. M. et al., 1992). 
 
Although plaques and tangles are the major neuropathological hallmarks in AD, it has 
been a challenge to find a link between the two. The leading belief is that tangle 
formation occurs downstream of Aβ plaque formation in the disease progression. 
Strong evidence for this comes from a recent study published by Jin et al. who have 
shown that Aβ dimers isolated from Alzheimer cortices directly induce tau 
hyperphosphorylation in hippocampal neuronal cultures (Jin M. et al., 2011). This led to 
disruption of the cytoskeleton leading to neuritic degeneration. These changes could be 
reversed by knocking down tau and aggravated by overexpressing tau. In line with 
these findings, recent evidence suggests that reduction in endogenous tau in mice 
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rescues Aβ mediated learning and memory deficits in a dose dependent manner 
(Roberson E. D. et al., 2007). This suggests that Aβ toxicity is mediated by tau. One 
molecular mechanism underlying this was suggested to be the mislocalisation of tau to 
dendritic spines. Here, tau causes reduction in α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors. 
Furthermore, mislocalised tau causes an aberrant localisation of Fyn kinase, which 
phosphorylates NMDA receptor subunits, to dendrites, leading to excitotoxic 
downstream signalling. All these effects were markedly reduced in Tau-/- mice 
corroborating the above findings (Ittner L. M. et al., 2010, Hoover B. R. et al., 2010).  
 
2.4.6 Inflammation in AD 
 
Besides the hallmark plaques and tangles, a prominent inflammatory and innate 
immune response is also seen in AD (McGeer P. L. et al., 1995, Rogers J. et al., 1996). 
Activated microglia, the macrophages of the central nervous system (CNS), and 
astrocytes are the main cells that participate in neuroinflammation. However, 
infiltration by adaptive immune system cells such as B and/or T lymphocytes is limited 
in AD. Post mortem studies of AD brains have revealed abnormal expression of 
cytokines, complement proteins and other immune and inflammatory mediators 
(reviewed in Akiyama H. et al., 2000). Epidemiological studies have indicated that the 
use of non-steroidal anti-inflammatory drugs (NSAIDs) reduced the risk of AD 
(Thomas T. et al., 2001). Current hypothesis suggests that inflammation arises as a result 
of the Aβ plaque formation, and is initially a beneficial response intended to limit the 
disease. Evidence for this comes from studies showing that active or passive 
immunization with Aβ antibodies reduces Aβ accumulation and rescues functional 
deficits. In contrast, defects in microglial function promote AD (Monsonego A. et al., 
2003). However, as the inflammation becomes chronic, it starts to have deleterious 
effects and instead becomes neurotoxic.  
 
2.4.7 Current hypotheses in AD: The amyloid cascade and dual pathway hypotheses 
 
The AD field has been dominated by the amyloid cascade hypothesis put forward by 
Drs. John Hardy and David Allsop in 1991 (Hardy J. et al., 1991). The hypothesis states 
that the factor triggering the onset of the disease is increased production of Aβ (Figure 
4). In FAD and EOAD, this is due to causative mutations in APP, PSEN1 and PSEN2 
genes, leading directly to increased generation of Aβ and increased ratio of Aβ42 to 
Aβ40. In the sporadic cases, elevated Aβ levels arise from reduced clearance and 
degradation. In both cases there is a gradual accumulation of Aβ throughout life. 
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Oligomerization of especially Aβ42 causes synaptic toxicity. As these oligomers 
aggregate into diffuse plaques, this initiates an inflammatory response by activating the 
microglia and astrocytes. As a result, there is an increase in reactive oxidative species 
leading to oxidative damage which affects the activities of kinases and phosphatases 
leading to PHF and tangle formation. Ultimately, all these events result in widespread 
neuronal and synaptic damage, neurotransmitter system deficits, and eventually 
dementia. The main evidence for this hypothesis comes from the fact that all known 
mutations in the APP, PSEN1 and PSEN2 genes increase Aβ production. Also, DS 
patients have increased Aβ production due to increased APP gene load and all DS 
patients invariably develop AD-type dementia. Finally, mouse models of AD 
expressing mutant human APP develop Aβ plaques and present with neuronal damage 
and memory deficits similar to those seen in human AD patients. The hypothesis has 
since been updated and revisited (Selkoe D. J., 2000). 
 
In 2009, Drs. Karen Duff and Scott Small put forward a dual pathway hypothesis 
whereby amyloid formation and tau aggregation occur independently, and 
subsequently together lead to neuronal loss and dementia (Small S. A. et al., 2008, see 
Figure 4). The authors argued that while the amyloid cascade hypothesis was based on 
the rare EOAD cases, it did not fit well with explaining the greater part of the AD cases, 
i.e., sporadic AD which is a much more complex disease with multiple factors playing a 
role in conjunction. Firstly, many drug trials aiming at reducing the Aβ burden in the 
brain have failed to improve cognition in the patients. A historical drug trial worth 
mentioning was the first active immunization trial where antibodies against Aβ were 
given to a cohort of patients (Holmes C. et al., 2008). However, the trial had to be halted 
due to lethal meningeal encephalitis in some patients. Still, the patients were followed 
over a period of six years and post mortem analysis of eight patients revealed a 
significant reduction in the Aβ plaque burden. However, the cognitive capacities of the 
same patients declined through the follow-up period to the point where patients were 
incapable of partaking in the cognitive examination due to complete impairment (Small 
S. A. et al., 2008). Secondly, the most important risk gene in AD, APOE, has been shown 
to affect both Aβ and tau phosphorylation. Several studies provide evidence that the ε4 
allele of APOE is less efficient at mediating Aβ clearance, hence causing increased Aβ 
levels in the brain (Bales K. R. et al., 2002, DeMattos R. B. et al., 2004, Dodart J. C. et al., 
2005). However, a separate set of mechanisms have been put forward linking APOE 
with tau hyperphosphorylation. APOE has been shown to regulate GSK3, one of the 
most important kinases phosphorylating tau and APOEε4 activates GSK3 (Cedazo-
Minguez A. et al., 2003, Hoe H. S. et al., 2006, Ohkubo N. et al., 2003). Both the 
hypotheses are represented in Figure 4. 
 
 Recent evidence suggests that
toxicity. For example, mit
pathological mechanism med
Reddy P. H. et al., 2008). Bo
different mechanisms. Conse
APP, PS2 and tau) exhibit a
expressing APP or tau alone (
has been shown to mediate A
tau-/- neurons being resista
dysfunction (Rapoport M. et a
 
 
Figure 4. Schematic representa
dual pathway hypothesis. Acco
levels, either due to increased
gene load in the case of duplic
as APOEε4 allele, leads to a c
clearance of Aβ. This triggers 
neuronal loss and neurotransm
(Hardy J. et al., 1991). Howev
and tangle formation are indep
dementia. (Modified from the a
and Small S. A. et al., 2008).  
 
23 
 Aβ and tau might act synergistically to me
ochondrial dysfunction is considered 
iating neuronal death in AD (Hauptmann
th Aβ and tau impair mitochondrial fu
quently, triple transgenic AD mice (exp
ggravated mitochondrial dysfunction com
Rhein V. et al., 2009, Ittner L. M. et al., 2011)
β toxicity. Evidence for this comes from 
nt to Aβ toxicity and Aβ-induced ax
l., 2002, Vossel K. A. et al., 2010).  
tion of the amyloid cascade hypothesis and 
rding to the amyloid cascade hypothesis, an
 generation as the result of causative muta
ations, or reduced clearance due to susceptib
hronic imbalance between production and d
a cascade of events eventually leading to ta
itter system disturbance leading to dementi
er, the dual hypothesis states that amyloid p
endent events but both in concert lead to ne
myloid cascade hypothesis diagram from ww
diate neuronal 
an important 
 S. et al., 2006, 
nction, but via 
ressing mutant 
pared to mice 
. Moreover, tau 
observations of 
onal transport 
 
the more recent 
 increase in Aβ 
tions, increased 
ility genes such 
egradation and 
ngle formation, 
a and AD onset 
laque formation 
uronal loss and 
w.alzforum.org 
24 
 
Various other hypotheses have also been put forward but have received less attention 
such as neuroinflammation hypothesis, oxidative stress hypothesis, axonal transport 
dysfunction hypothesis, disturbed lipid homeostasis hypothesis, chronic stress 
hypothesis, NMDA receptor dysfunction hypothesis etc. (Bertram L, McQueen M, 
Mullin K, Blacker D, Tanzi R. The AlzGene Database. Alzheimer Research Forum. 
Available at: http://www.alzforum.org/res/adh/cur/default.asp. Accessed 2011.04.28). 
 
2.5 PROTEIN AGGREGATION 
 
Protein misfolding and polymerization leading to protein aggregation is a common 
feature among many neurodegenerative diseases (Hol E. M. et al., 2006), whether it is 
Aβ and tau in AD, α-synuclein in PD or huntingtin in HD. In the case of PD, α-
synuclein aggregation is prompted by protein misfolding. As a result, a population of 
misfolded, partially-folded or unfolded proteins is formed, leading to nucleation of 
oligomeric clusters of α-synuclein. In the final stage of the aggregation process, 
insoluble fibrillar aggregates are formed (Uversky V. N., 2003). In AD, the main protein 
aggregates consist of Aβ fibrils and PHFs of tau. PHF are intracellular highly insoluble 
and stable filaments while Aβ fibrils are mostly extracellular deposits surrounded by 
dystrophic dendrites and axons and activated microglia and astrocytes (Selkoe D. J., 
1994). The dystrophic neurites and axons in the vicinity of the plaques suggest that Aβ 
fibrils are directly toxic to neurons (Selkoe D. J., 1994). The main component of an 
amyloid deposit is the protein fibril. Protein fibrils have high β-sheet content where the 
sheets are typically parallel to the direction of the fibril and the strands run 
perpendicular to the fibril (Uversky V. N., 2003).  
 
A wide range of amyloid deposits can be found in AD brains including faint deposits, 
neuritic plaques rich in glia and even plaques of dense amyloid deposits without any 
cytopathology. “Diffuse plaques” are loose and granular aggregates of mostly non-
fibrillar A (typically thioflavin S- and Congo red-negative) that lack the dystrophic 
neurites and inflammatory cells in their surroundings. These comprise mainly of Aβ42 
and little or no Aβ40 (Iwatsubo T. et al., 1994, Iwatsubo T. et al., 1995). It is believed that 
these are precursor lesions to late stage neuritic plaques. Of the two most common Aβ 
species, Aβ40 and Aβ42, the longer Aβ42 is more hydrophobic and considered more 
fibrillogenic and toxic. The extra two amino acids in the end enhance the misfolding 
and aggregational propensity of the peptide (Selkoe D. J., 1994). On the other hand, the 
dense core plaques contain a core formed by Aβ42 peptide surrounded by a “halo” of 
Aβ40 peptides (Selkoe D. J., 1994).  
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The role of Aβ oligomers, as opposed to diffuse and/or dense plaques, as the drivers of 
neurodegeneration has gained momentum in recent years. The levels of soluble Aβ 
oligomers and cognitive impairment show significant correlations (Naslund J. et al., 
2000, McLean C. A. et al., 1999, Lue L. F. et al., 1999). Also at the functional level, in 
mouse models, synaptic dysfunction and cognitive decline was visible before plaque 
formation suggesting that the soluble oligomers were to blame (Larson J. et al., 1999, 
Moechars D. et al., 1999, Hsia A. Y. et al., 1999, Mucke L. et al., 2000). Furthermore, 
behavioural deficits in mice were reversed with Aβ antibody treatment without any 
reduction in plaques (Dodart J. C. et al., 2002). A more direct proof of the synaptotoxic 
role of Aβ oligomers came from experiments where direct microinjection of Aβ 
oligomers resulted in LTP inhibition and disruption of already learned behaviour in 
rodents (Walsh D. M. et al., 2002). Taken together, these results suggest that amyloid 
plaques maybe less toxic as compared to soluble Aβ oligomers, which directly 
compromise synaptic function and memory formation and retrieval.  
 
Present understanding suggests that PHF formation is a secondary response to an 
insult, such as the Aβ accumulation, causing neuronal dysfunction in AD. Proof of this 
comes from FTD where mutations in the MAPT gene directly cause the disease (Hutton 
M. et al., 1998, Poorkaj P. et al., 1998, Spillantini M. G. et al., 1998, Galimberti D. et al., 
2010). However, no Aβ deposits are found in these patients (Selkoe D. J., 1994). In 
contrast, in AD, APP mutations invariably lead to hyperphosphorylation of tau. 
Moreover, PHF formation of wild-type tau shows that Aβ plaque formation can cause 
PHF formation but not vice versa (Hutton M. et al., 1998, Poorkaj P. et al., 1998, 
Spillantini M. G. et al., 1998). Functionally, the hyperphosphorylation of tau leads to its 
detachment from microtubules and destabilization of the local cytoarchitecture and 
organelles (Barghorn S. et al., 2002). The detached hyperphosphorylated tau molecules 
can aggregate with each other to form insoluble PHF which cause further structural 
disruption of axonal structure and transport. In addition to dysregulated 
phosphorylation/dephosphorylation balance, several other post-translational 
modifications of tau appear to modulate its tendency to aggregate. These include 
proteolytic processing (e.g. calpains, caspases) and acetylation (Yang X. J. et al., 2008, 
Petrucelli L. et al., 2004, Min S. W. et al., 2010). Like with Aβ, tau oligomers have also 
been reported to exert neurotoxic effects on neurons in the same way as Aβ oligomers 
(Maeda S. et al., 2007). 
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2.6 GRANULIN/PROGRANULIN 
 
FTD is the second most common early-onset neurodegenerative disease after AD 
(Mendez M. F. et al., 2008). Symptoms include prominent personality changes and 
language impairment. At later stages, patients also present dementia and cognitive 
impairment. Neuropathology reveals frontal and anterior temporal lobar atrophy. FTD 
can be divided into two types: FTDP-17 and FTDU-17. FTDP-17 or FTD with 
Parkinsonian symptoms is an autosomal dominant disorder caused by mutations in 
MAPT and is associated with tau deposition in neurons and glial cells (Mendez M. F. et 
al., 2008, Seelaar H. et al., 2010). In contrast, FTDU-17 is FTD caused without mutations 
in MAPT and tau deposits. However, neurons in these cases contain cytoplasmic and/or 
nuclear inclusions that are positive for ubiquitin. Interestingly, all cases with mutations 
in the GRN gene, encoding progranulin (PGRN), show a FTDU phenotype. These 
mutations cause a 50% decrease in either GRN mRNA or PGRN levels, leading to 
haploinsufficiency of the protein. As PGRN is related to neuronal survival, reduced 
protein levels lead to neuronal loss and dementia. However, interestingly there have 
also been reports of cases of FTDU where mutations in MAPT and PSEN1 have been 
found indicating possible overlap between FTDP and FTDU (Seelaar H. et al., 2010).  
 
The GRN gene is found on chromosome 17q21 and encodes for the protein PGRN, a 
593-amino acid polypeptide with an estimated molecular weight of 68.5 kDa (Daniel R. 
et al., 2003). PGRN is cleaved by extracellular proteases to produce smaller polypeptides 
known as granulins which have a range of biological functions (Daniel R. et al., 2003). In 
the periphery, PGRN has been implicated as an immunoregulator in inflammation and 
in the early stages of wound repair. PGRN in wounds increases neutrophil and 
macrophage infiltration and increases neovascularization in a similar manner as 
vascular endothelial growth factor (He Z. et al., 2003).  
 
It is widely recognized that dementia symptoms are rarely present alone. Especially in 
the later stages of disease, multiple pathologies can be present with AD patients 
showing symptoms of other dementias as well. Considering the crucial component of 
GRN in the susceptibility for FTD, it would be interesting to investigate what role GRN 
might play in the susceptibility to other dementias. A similar approach was also used 
by Brouwers et al., who showed that a haplotype consisting of SNPs in the GRN gene 
were over-represented in a Belgian AD cohort (Brouwers N. et al., 2008). 
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2.7 UBIQUILIN-1 
 
Ubiquilin-1, also known as PLIC-1, was first described by Mah et al. in 2000 as a novel 
PS-interacting protein that stabilised PS (Mah A. L. et al., 2000). Subsequently, ubiquilin-
1 was shown to modulate PS ubiquitination and degradation, and levels of other γ-
secretase components, implying its relevance in AD (Massey L. K. et al., 2004, Massey L. 
K. et al., 2005). Furthermore, a direct genetic association was reported in 2005, where 
Bertram et al. showed that an intronic SNP downstream of exon 8 in the UBQLN1 gene 
was significantly associated with AD (Bertram L. et al., 2005). This risk allele led to an 
increase in the mRNA levels of transcript variant 2 (TV2) of ubiquilin-1 in the brain of 
human AD patients, increasing the ratio of TV2 vs. TV1 mRNA levels in a dose-
dependent manner (Bertram L. et al., 2005). These findings point towards a role for TV2 
that is relevant especially in the context of AD. However, contradictory studies have 
also been published showing no genetic association between UBQLN1 and AD 
(Brouwers N. et al., 2006b, Smemo S. et al., 2006).  
 
Since the initial studies of the effects of ubiquilin-1 on PSs and γ-secretase modulation, 
much more is known now regarding the functional effects of ubiquilin-1 in AD. 
Ubiquilin-1 downregulation has been shown to increase APP maturation, processing 
and Aβ generation in human neuroglioma H4 and human embryonic kidney HEK293 
cells (Hiltunen M. et al., 2006). Ubiquilin-1 overexpression was also shown to alleviate 
ER stress, a process that is especially relevant in the context of AD (Lu A. et al., 2009). 
Antibodies against ubiquilin-1 have been shown to stain NFTs in AD and also Lewy 
bodies in PD, suggesting a role for ubiquilin-1 beyond AD in other neurodegenerative 
diseases as well (Mah A. L. et al., 2000).  
 
Ubiquilin-1 is a ubiquitin-like protein that binds specific proteins and mediates their 
proteasomal degradation. These proteins include PSs, cyclin A, γ-aminobutyric acid 
(GABA) receptor and hepatitis C virus RNA-dependent RNA polymerase (Mah A. L. et 
al., 2000, Funakoshi M. et al., 1999, Bedford F. K. et al., 2001, Gao L. et al., 2003). 
Ubiquilin-1 has also been shown to interact with proteins such as mammalian target of 
rapamycin (mTOR), basic helix-loop-helix (bHLH) transcription factors, integrin-
associated protein CD44, heterotrimeric G-protein and nicotinic acetylcholine receptors 
(nAChRs; Wu A. L. et al., 1999, Wu S. et al., 2002, Persson P. et al., 2004, N'Diaye E. N. et 
al., 2003, Ficklin M. B. et al., 2005). By mediating the degradation of unassembled 
nAChRs, ubiquilin-1 regulates the insertion of nAChRs in the plasma membrane, 
thereby playing a direct role in neuronal signalling (Ficklin M. B. et al., 2005). In 
contrast, ubiquilin-1 enhances the membrane insertion of GABA receptors, thus 
enhancing inhibitory signalling (Bedford F. K. et al., 2001, Ficklin M. B. et al., 2005, Saliba 
R. S. et al., 2008) 
28 
 
 
The protein structure of ubiquilin-1 consists of the characteristic C-terminal ubiquitin-
associated (UBA) and N-terminal ubiquitin-like (UBL) domains. The UBL domain 
mediates the interaction with the ubiquitin-interacting motif of the 19S subunit of the 
proteasome, while the UBA domain binds poly- but not mono- ubiquitinated proteins 
(Mah A. L. et al., 2000, Zhang D. et al., 2008). In this way, ubiquilin-1 functions as a 
bridge between the ubiquitination and degradation machineries in the cell.  
 
UBQLN1 is found on chromosome 9q22 and contains 11 exons (Mah A. L. et al., 2000). 
So far, four naturally occurring alternatively spliced TVs have been identified in the 
brain. TV1 is the full-length form containing all the 11 exons. TV2 has exon 8 spliced out 
while TV3 lacks exons 2, 3 and 4. TV4 is the shortest TV with only exons 1, 2 and 3 
present followed by a unique C-terminus (Lu A. et al., 2009). A schematic representation 
of the four TVs is found in Figure 5. 
 
 
 
Figure 5. Schematic representation of the four known ubiquilin-1 TVs, TV1, TV2, TV3 and 
TV4 with their respective sizes in kDa. The UBA and UBL domains are  indicated. Black dots 
represent asparagine- and proline-rich repeats which may mediate protein-protein 
interactions (Reprinted with permission from John Wiley and Sons). 
 
The four TVs have been suggested to have different physiological properties in cell-
based studies. For example, in the alleviation of ER-stress, TV3 showed the most 
prominent effect compared to TV1 and TV2, while TV4 had no effect (Lu A. et al., 2009). 
Taken together, present findings suggest that ubiquilin-1 TVs play an important role in 
APP processing and Aβ generation but are also associated with Aβ-independent 
pathways that modulate neuronal homeostasis.  
 
Abnormal accumulation of ubiquitinated proteins is a common hallmark in a number of 
neurodegenerative diseases such as AD, PD and HD (Hol E. M. et al., 2006). It has been 
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suggested that this aggregation is likely the result of an overwhelmed or dysfunctional 
ubiquitin-proteasome system (UPS) or the unfolded protein response (UPR; Hol E. M. et 
al., 2006). Under normal cellular conditions, the UPS mediates degradation of 
ubiquitinated proteins (Hol E. M. et al., 2006). These can be normal proteins that are not 
required any longer or proteins that are unfolded or misfolded. However, in conditions 
of cellular stress, such as oxidative stress or infection, the UPS can get challenged. To 
overcome this, the cell starts to express heat shock proteins that recognise and target 
misfolded and unfolded proteins for degradation by the UPS (Hol E. M. et al., 2006). 
However, if the UPS gets overwhelmed, misfolded proteins start to accumulate in the 
cell. The cell then activates the UPR. The main objective of the UPR is to restore normal 
cellular function by increasing chaperone expression and halting protein translation 
(Hol E. M. et al., 2006). Since ubiquilin-1 is a shuttle between ubiquitinated proteins and 
the UPS, its effects on protein aggregation are highly relevant in the context of 
neurodegenerative diseases. Not surprisingly, the UBL and UBA domains which are 
required for mediating protein degradation have been proven essential in aggresome 
formation and targeting of aggresomes to autophagosomes (Heir R. et al., 2006, N'Diaye 
E. N. et al., 2009).  
 
Formation of aggresomes was first described by Johnston et al. as a cellular response to 
accumulation of misfolded proteins (Johnston J. A. et al., 1998). Aggresomes are formed 
when the capacity of the proteasome is exceeded by generation of aggregation-prone 
misfolded proteins. Aggresomes are characterized as cytoplasmic inclusions of 
ubiquitinated aggregated proteins that are not degraded by the proteasome (due to a 
dysfunctional/overwhelmed UPS). Instead, these aggregates are transported along the 
microtubules to the microtubule-organising centre (MTOC), which is juxtanuclear, to 
form an aggresome. As a result, the aggresome causes an indentation against the 
nuclear membrane. Aggresomes are typically covered by the intermediate filament 
protein vimentin that forms a cage around the aggresome (Olzmann J. A. et al., 2008, 
Kopito R. R., 2000). It is believed that this might be a mechanism to render the otherwise 
possibly harmful aggregated proteins harmless by preventing aberrant protein 
interactions. Misfolded and/or unfolded proteins are highly harmful in the cell as they 
have the capacity to seed the misfolding and aggregation of neighbouring normal 
proteins (Uversky V. N., 2003). Aggresomes have been suggested to be discarded by 
autophagy and subsequent lysosomal degradation (Olzmann J. A. et al., 2008, Kopito R. 
R., 2000). Taken together, current hypothesis suggests that aggresomes are a 
cytoprotective mechanism to handle excess unfolded proteins when the UPS gets 
overwhelmed during stress situations.  
 
UPS dysfunction in AD has other more wide-ranging effects than aggresome formation 
and protein accumulation. One of the earliest effects of UPS dysfunction in AD is 
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believed to be synaptic dysfunction (Hegde A. N., 2004, Bingol B. et al., 2005). The main 
reason for this is that the UPS is responsible for degradation of proteins involved in 
synaptic plasticity, which is critical for maintenance of synaptic integrity and normal 
synaptic functions (Hegde A. N., 2004, Bingol B. et al., 2005). Moreover, the UPS can 
directly be inhibited by Aβ and PHFs of tau in vitro, either by interfering with ubiquitin 
conjugation or direct interaction and inhibition of the proteasome (Wirths O. et al., 2006, 
Wirths O. et al., 2007, Keck S. et al., 2003). 
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3. Aims 
 
The overall aim of this thesis was to genetically and functionally characterise novel risk 
genes that affect AD pathogenesis and to elucidate the underlying molecular 
mechanisms behind these effects. 
 
The specific aims were as follows: 
 
1.  To determine the frequency of APP duplications in Finnish AD patients (Study I). 
 
2.  To determine whether GRN gene associates with AD (Study II).  
 
3.  To identify the role of ubiquilin-1 transcript variants TV1 and TV3 in PS1 
accumulation and to characterise the inclusion bodies resembling aggresomes that 
contained accumulated PS1 (Study III). 
 
4.  To summarise the findings from study III and review current literature regarding 
the role of ubiquilin-1 in protein aggregation and aggresome formation (Paper IV).  
 
5.  To investigate the role of ubiquilin-1 transcript variants TV1 and TV2 in the 
molecular pathways relevant to the pathogenesis of AD (Study V). 
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4. Materials and Methods 
 
4.1 SUBJECTS (STUDY I, II) 
 
All subjects in study I and II originated from Eastern Finland (Table 2.). The diagnosis 
for probable AD was performed according to the NINCDS-ADRDA criteria at the 
Kuopio University Hospital. Study I consisted of 64 probable AD patients whose onset 
age of disease was ≤65 years. Thirty subjects were diagnosed with familial EOAD with 
at least two affected first-degree relatives in two generations. The remaining 34 subjects 
were diagnosed with sporadic EOAD. None of the subjects carried mutations in APP, 
PSEN1 and PSEN2 genes. The cohort for study II consisted of 512 AD patients and 649 
age-matched controls. The AD subjects had a mean age at onset of 71 ± 7 years. The 
control subjects were confirmed to show no signs of dementia based on 
neuropsychological testing using the following tests (Hanninen T. et al., 2002):  
 Memory: Buschke Selective Reminding Test, Visual Reproduction Test from 
Wechsler Memory Scale, Logical Memory Test from Wechsler Memory Scale-
Revised 
 Language: Abbreviated (15 items) Boston Naming Test 
 Attention and executive function: Verbal Fluency Test, Trail Making Test parts A 
and B 
 Global functioning: Mini-Mental State Examination 
Both studies were approved by the Ethics Committee of the Kuopio University 
Hospital.  
 
Table 2. Demographic data of subjects used in study I and II. 
 
Study Number  Mean age at onset 
± SD 
Age range % Women 
Study I Total = 64 59.7 ± 5.3 45 - 65 72 
Study II Total = 1161    
 Probable AD = 512 71 ± 7 43 - 89 68.8 
 Controls = 649 69 ± 6* 37 - 87 59.6 
 
*Mean age at neuropsychological examination 
 
4.2 qPCR AND qmPCR (STUDY I) 
 
The APP gene dosage in the 64 Finnish EOAD samples was measured from DNA 
extracted from peripheral blood lymphocytes. Primers targeting APP16i (intron after 
exon 16) and APP5e (exon 5) were used to measure APP gene dosage using qPCR and 
qmPCR (see Table 3 for primer sequences). The PCR reactions were performed in Peltier 
Thermal Cycler-200 (PTC-200) machines (MJ Research). Hemoglobin beta (HBB) on 
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chromosome 11 was used as a control gene. The qPCR reaction volume was 25 µl 
containing 25 ng of genomic DNA, 2x SYBR Green PCR Master Mix (Applied 
Biosystems) and 600 nM of each primer. Each 96-well plate contained four DS patient 
samples as positive controls of increased gene dosage, and four healthy controls. All 
samples were analysed in duplicates and APP gene dosage was calculated using the 
standard curve method (Applied Biosystems). All samples were normalised to HBB 
levels. 
 
Table 3. Sequences of primers used in Study I 
 
Primer Sequence 
APP intron after exon 16 
APP16iF CCCCACAATTACACTAACGCCTAT 
APP16iR GTCCAGTAGAGGGAGCTGATTCTC 
APP Exon 5 
APPEx5F TGCCCACTGGCTGAAGAAA 
APPEx5R GTCATCCTCCTCCGCATCA 
β-Globin 
β-globinF TGGGCAACCCTAAGGTGAAG 
β-globinR GTGAGCCAGGCCATCACTAAA 
 
The qmPCR reaction was a multiplex reaction where fluorescein amidite (FAM)-
labelled forward primers for APP16i (100 nM), APP5e (200 nM) and HBB (200 nM) were 
combined with 25 ng of genomic DNA, 10x buffer, 10 mM dNTP and 2.5 U HotStarTaq 
(Qiagen). The PCR reaction was performed using PTC-200 machines (MJ Research). One 
µl of the PCR product was then mixed with 10 µl HiDi Formamide and 0.75 µl 
GeneScan 600 LIZ Size Standard (Applied Biosystems) and denatured at 95°C for 3 
minutes. The samples were then analysed using ABI 3100 (Applied Biosystems) 
capillary electrophoresis system and the results were viewed using GeneMapper 3.0 
software (Applied Biosystems). All samples were normalised to HBB levels. The height 
of peaks was used to calculate gene dosage and all samples were normalised to healthy 
controls.  
 
4.3 SNP ANALYSIS (STUDY II) 
 
TaqMan Master Mix (Applied Biosystems, Foster City, CA) was used to genotype SNPs 
using PCR primers for rs850714, rs3785817, rs4792939, rs850713, rs5848, and rs850737 in 
the GRN gene. The PCR reactions were performed in PTC-200 machines (MJ Research) 
and ABI2720 Thermal Cycler machines (Applied Biosystems). As a quality control 
measure, 10 % of the samples were genotyped in duplicate to measure the accuracy of 
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the genotyping. The accuracy was 100%. The APOE genotyping was performed as 
previously (Tsukamoto K. et al., 1993).  
 
4.4 cDNA CONSTRUCTS (STUDY III, V) 
 
cDNA constructs containing the ubiquilin-1 TVs namely TV1, TV2, TV3 and TV4 were 
used (listed in Table 4). Tagged TV1, TV2 and TV3 constructs containing a myc tag at 
the 5’-end yielding N-terminal myc tagged myc-TV1, myc-TV2 and myc-TV3 were also 
used. Additionally, to aid visualisation of TV1 and TV3, we created myc and 
monomeric red fluorescence protein (mRFP) tagged myc-TV1-mRFP and myc-TV3-
mRFP expression vectors. The myc tag added ~3 kDa and myc-mRFP tag added ~39 
kDa to the molecular weight of the TVs. Western blot analysis of protein lysates from 
HEK293-AP-APP cells (see section 4.5.1) overexpressing myc-TV1-mRFP and myc-TV3-
mRFP showed that they behaved similarly as wild-type TV1 and TV3. Control plasmids 
used were pcDNA 3.1, HIV-pBOB and mRFP. Other plasmids used were FE65 and full-
length LAR tagged with V5-His tag (~5 kDa) at the 3’ end producing FL-LAR-V5-His.  
 
Table 4. List of cDNA constructs used in studies III and V. 
 
cDNA construct Tag Promoter 
FE65† - CMV 
FL-LAR-V5-His† V5, His CMV 
HIV-pBOB (Control plasmid)*† - CMV 
mRFP (Control plasmid)* - CMV 
myc-TV1*† myc CMV 
myc-TV2† myc CMV 
myc-TV3*† myc CMV 
myc-TV1-mRFP* myc, mRFP CMV 
myc-TV3-mRFP* myc, mRFP CMV 
pcDNA 3.1 (Control plasmid)*† - CMV 
PS1* - CMV 
TV1*† - CMV 
TV2*† - CMV 
TV3* - CMV 
TV4* - CMV 
 
*Study III  
†Study V 
 
4.5 CELL CULTURES AND TRANSFECTIONS (STUDY III, V) 
4.5.1 Secondary cell lines 
 
The secondary cell lines used in study III and V are listed in Table 5. Cell cultures of 
human embryonic kidney cells stably overexpressing alkaline-phosphatase-conjugated 
APP (HEK293-AP-APP; Lichtenthaler S. F. et al., 2003) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 
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mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, 50 µg/ml 
hygromycin and 0.3 µg/ml puromycin. Human neuroblastoma SH-SY5Y cells stably 
overexpressing APP751 (SH-SY5Y-APP751) and human neuroglioma H4 cells stably 
overexpressing TV1 or TV3 (H4-TV1, H4-TV3) were cultured in DMEM supplemented 
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 200 
µg/ml geneticin. HEK293T cells stably overexpressing ubiquitinG76V-yellow fluorescent 
protein (UbG76V-YFP; Menendez-Benito V. et al., 2005) were used in reporter cell 
experiments and cultured in DMEM containing 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 400 µg/ml geneticin. All cells were cultured in a 
humidified cell culture incubator in 5% CO2. 
 
For transfections, HEK293-AP-APP cells were cultured on poly-D-lysine (PDL, 0.1 
mg/ml)-coated plates when forward- or reverse-transfected. All cell lines were 
transfected using Lipofectamine 2000 reagent (Invitrogen) according to manufacturer’s 
instructions. The cells were allowed to transfect overnight and the medium was 
changed after 24 hours. The cells were analysed after 48 hours. For reporter cell 
experiments, HEK293T UbG76V-YFP cells were transfected using electroporation and 
plated on polyethyleneimine-coated glass cover-slips.  
 
Overexpression of TV1 in SH-SY5Y-APP751 cells was robust and GAPDH-normalised 
TV1 levels increased 8-9 fold on average when compared to endogenous TV1 levels in 
control transfected cells. In HEK293-AP-APP cells, transient overexpression of the TVs 
with PS1 led to an average ~3 fold overexpression of GAPDH-normalised TV1 and TV2 
levels as compared to endogenous levels. The endogenous levels of TV3 and TV4 were 
undetectable. Therefore, we measured their overexpression as a ratio of TV3 levels to 
those of the endogenous TV1 (= 0.6 ± 0.1), and the ratio of TV4 levels to the endogenous 
TV1 levels (= 2.0 ± 0.8), in each sample (analysed in section 4.7). 
 
4.5.2 Primary cortical cells  
 
Primary cortical cells from APP/PS1Δ9 transgenic mice (Jankowsky J. L. et al., 2001) 
were harvested at embryonic day 18 and plated at ~200000 cells/well in PDL-coated 12-
well plates. The cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified cell culture 
incubator in 5% CO2. After cell attachment, the medium was replaced with serum-free 
Neurobasal medium containing B27 supplement and 2 mM L-glutamine. Half of the 
Neurobasal medium was refreshed every four days.  
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For transfections, cells that had matured over 12 days were used. Transfection was 
carried out through magnetofection using NeuroMag (OZ Biociences) according to 
manufacturer’s instructions. The cultures were composed of approximately 95% 
neurons and 5% glia. The cells were cultured for 48 hours and analysed.  
 
Table 5. List of cell lines and primary cells used in studies III and V. 
 
Secondary cell lines  
SH-SY5Y-APP751† Stably overexpressing APP751 (Sarajarvi T. et al., 2009) 
SH-SY5Y-BACE1† Stably overexpressing BACE1 (Sarajarvi T. et al., 2009) 
HEK293-AP-APP* Stably overexpressing alkaline phosphatase-conjugated APP 
(Lichtenthaler S. F. et al., 2003) 
HEK293T-UbG76V-YFP* Stably overexpressing ubiquitin containing G76V mutation tagged with 
YFP (Menendez-Benito V. et al., 2005) 
H4-TV1† Stably overexpressing TV1 (Lu A. et al., 2009, Sarajarvi T. et al., 2009) 
H4-TV3† Stably overexpressing TV3 (Lu A. et al., 2009, Sarajarvi T. et al., 2009) 
 
Primary cells 
 
APP/PS1Δ9* Mixed cortical neuronal culture from transgenic mice overexpressing 
mouse APP695 harboring a human Aβ domain and Swedish mutations 
K595N and M596L and human PS1 with the deletion of exon 9 
(Jankowsky J. L. et al., 2001) 
 
*Study III  
†Study V 
 
4.6 SECRETED APP AND Aβ MEASUREMENTS (STUDY III, V) 
 
SH-SY5Y-APP751 cells were plated at a density of ~800000 cells/well in 6-well plates 
(Nunc) in 2 ml of medium. The cells were transfected and medium changed to 1 ml 
after 24 hours. Forty eight hours after transfection, secreted APPα and secreted APP 
total (sAPPtot) levels were measured from 30 µl of cell culture medium using Western 
blotting. Aβ40 and Aβ42 levels were measured using enzyme-linked immunosorbent 
assay (ELISA) kit (The Genetics Company) according to manufacturer’s instructions 
and were normalised to total protein levels of the corresponding protein lysates.  
 
sAPPtot measurements from HEK293-AP-APP cells was performed by heat-inactivating 
culture medium at 65°C for 30 minutes. Twenty µl of this medium was added to 200 µl 
of reaction solution with 5 mg of p-nitrophenyl (Sigma) as the substrate. Absorbance 
was read at 405 nm and each experiment was carried out in triplicate. Aβx-40 and Aβx-
42 levels were measured using sandwich ELISA assay and levels were normalised to 
total protein levels.  
 
Primary cortical cells were plated at ~200000 cells/well in 12-well plates (Nunc) in 1 ml 
of medium. Aβ40 and Aβ42 levels from primary cortical cell culture media were 
measured 48 hours after transfection using ELISA assay kit (The Genetics Company) 
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according to manufacturer’s instructions and were normalised to total protein levels of 
the corresponding protein lysates.  
 
4.7 WESTERN BLOT ANALYSIS (STUDY III, V) 
 
Cells were washed twice with cold phosphate buffered saline (PBS) and lysed using 
protease inhibitor-supplemented TPER tissue protein extraction buffer (Pierce). The 
lysates were centrifuged at 10000 x g for 10 minutes and proteins in the supernatant 
were measured using BCA protein assay kit (Pierce). Proteins were denatured by 
heating at 55°C and separated on 4-12% Bis-Tris gels (Invitrogen) and transferred to 
polyvinylidene difluoride membranes (Amersham Hybond-P). Blots were probed using 
the primary antibodies mentioned in Table 6. 
 
Table 6. List of primary antibodies used in studies III and V. 
 
Antibody Origin Detects Supplier Dilution 
WB* 
Dilution 
IF† 
APH1A Rabbit  Calbiochem, PC728 1:1000 - 
APP-A8717 Rabbit C-terminus Sigma 1:2000 - 
APP-22C11 Mouse N-terminus Millipore, MAB348 1:1000 - 
APP-6E10 Mouse  N-terminus of 
Aβ region 
BioSite, SIG39320 1:1000 - 
β-tubulin Mouse  Sigma 1:1000 - 
FE65 Goat  Santa Cruz Biotech, SC-
19751 
1:1000 - 
GAPDH Mouse  Abcam 1:15000 - 
Myc Mouse  Millipore, 05-724 1:1000 1:100 
Nicastrin Rabbit  ABR, PA1-758 1:1000 - 
PEN-2 Rabbit  Abcam, Ab18189 1:150 - 
PS1-5232 Mouse PS1-FL and 
PS1-CTF 
Chemicon, MAB5232 1:1000 1:400 
PS1-Ab14 Rabbit PS1-FL and 
PS1-NTF 
Gift from Dr. Samuel E. 
Gandy 
1:1000 - 
Transferrin 
receptor (TfR) 
Mouse  Zymed Laboratories, 12-
6800 
1:1000 - 
Ubiquilin-1 Mouse TV1-TV3 Zymed Laboratories, 34-
4400 
1:1000 - 
Ubiquilin-1 Rabbit TV1-TV3 Calbiochem 1:1000 - 
V5 Mouse  Invitrogen, R960-25 1:5000  
 
*WB: Western blot 
†IF: Immunofluorescence 
 
After primary antibody incubations, the blots were probed with appropriate secondary 
antibodies conjugated with horse radish peroxidase (GE Healthcare) and protein bands 
were detected using enhanced chemiluminescence substrate (ECL; Amersham 
Biosciences) and ImageQuant RT ECL Imager (GE Healthcare). Intensities of protein 
bands were quantified using Quantity One software (Bio-Rad) and protein levels were 
normalised to GAPDH, β-tubulin or transferrin receptor (TfR) levels.  
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4.8 CYCLOHEXIMIDE TIME COURSE EXPERIMENT (STUDY III) 
 
Cycloheximide is a compound that inhibits de novo protein synthesis making it possible 
to follow the degradation of the existing proteins over a time course. HEK293-AP-APP 
cells, reverse-transfected with TV1, TV3 or control plasmid, were split into five wells in 
PDL-coated 6-well cell culture plates. Cycloheximide was added to the cells at a 
concentration of 30 µg/ml and cells were harvested after 0, 1, 2, 4 and 8 hours of 
incubation. Proteins were analysed using Western blotting. Intensity values of PS1 full-
length (PS1-FL) at each time point was normalised to PS1-FL levels at 0 hours and 
plotted against hours of cycloheximide treatment to calculate the half-life of PS1-FL. 
Linear fitting was used to obtain the half-life.  
 
4.9 IN VITRO AICD GENERATION ASSAY (STUDY V) 
 
SH-SY5Y-APP751 cells transfected with TV1, TV2 or control plasmid were scraped in 
Buffer A (50 mM HEPES, 150 mM NaCl, 5 mM 1,10-phenanthroline monohydrate [PNT] 
pH 7.4). The samples were homogenised using a 25-gauge needle 10 times and 
centrifuged at 10000 x g for 15 minutes. The cytosolic fraction (supernatant) was used to 
confirm TV overexpression while the membranes (pellet) were resuspended in Buffer A. 
Equal amounts of membrane proteins from TV1, TV2 and control samples were 
incubated at +37°C for 2 hours to permit AICD generation. A sample incubated at +4°C 
was used as a negative control as AICD release is inhibited at this temperature. After 
the incubation, the samples were centrifuged at 10000 x g for 15 minutes and the 
generated AICD was collected in the supernatant. The pellet was resuspended in 
protease inhibitor-supplemented TPER and centrifuged as previously to release the 
remaining uncleaved CTFs. The AICD and CTF fractions were analysed using Western 
blotting and AICD levels were normalised to uncleaved C83 levels from the same 
samples. 
 
4.10 γ-SECRETASE ACTIVITY ASSAY (STUDY III) 
 
HEK293-AP-APP cells transfected with PS1 and TV1, TV3 or control plasmid were 
homogenised in Buffer B (20 mM HEPES pH 7.5, 150 mM KCl, 2 mM EGTA + protease 
inhibitor mixture [Thermo Scientific]) by using a 25-gauge needle 10 times and 
centrifuged at 100000 x g for 1 hour at +4°C. Cytosolic fractions (supernatant) were used 
to confirm TV overexpression by Western blotting. Membrane proteins in the pellet 
were washed with Buffer B and centrifuged at 100000 x g for 30 minutes. The pellet was 
resuspended in Buffer B + 1% CHAPSO and recentrifuged at 100000 x g for 30 minutes. 
Equal amounts of the membrane proteins from the final supernatant were incubated 
with 150 µl of substrate buffer (50 mM Tris-HCl pH 6.8, 2 mM EDTA, 0.25% CHAPSO) 
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and 8 µM substrate peptide overnight at +37°C. Samples treated with the γ-secretase 
inhibitor L685,458 at 100 µM were used as a negative control. Samples were briefly 
centrifuged and supernatants applied to a 96-well plate. Fluorescence was measured 
with an excitation wavelength of 355 nm and emission wavelength of 460 nm using 
Wallac 1420 VictorTM Multilabel Counter (PerkinElmer). The -secretase inhibitor 
L685,458 was used to control for the specificity of the assay and reduced the activity by 
an average 60%. 
 
4.11 CELL SURFACE BIOTINYLATION ASSAY (STUDY V) 
 
SH-SY5Y-APP751 cells transfected with TV1 or control plasmid were washed with PBS 
supplemented with 0.01 mM CaCl2 and 1 mM MgCl2 (PBS-Ca-Mg). The cells were pre-
incubated with PBS-Ca-Mg at +4°C for 15 minutes. The cells were then incubated with 
Sulfo-NHS-LC-Biotin (Pierce) in PBS-Ca-Mg at +4°C for 30 minutes. Excess biotin was 
quenched by incubating cells in PBS-Ca-Mg supplemented with 0.1 mM glycine for 20 
minutes. Cells were harvested in protease inhibitor-supplemented TPER and 
centrifuged at 10000 x g for 10 minutes. Fifty µg of proteins were incubated with 
binding buffer (PBS + 1% NP40) and agarose beads cross-linked with streptavidin 
(Pierce) over night. The biotinylated proteins were obtained by centrifuging the samples 
at 5000 x g for 1 minute to pellet the beads. The unbiotinylated proteins were found in 
the supernatant. The proteins were detached from the beads by boiling at 95°C for 10 
minutes. Both fractions were analysed using Western blotting. TV1 overexpression was 
confirmed from the unbiotinylated fraction. Total protein lysate was run beside the 
biotinylated fraction for comparison.  
 
4.12 COIMMUNOPRECIPITATION (STUDY V) 
 
Proteins were extracted from SH-SY5Y-APP751 cells transfected with TV1, FE65 or TV1 
and FE65. Sixty µg of protein was added to a final volume of 500 µl RIPA buffer (50 mM 
Tris pH 8.0, 150 mM NaCl, 2 mM EDTA and 0.5% Nonidet P40). Protein A/G agarose 
beads (Pierce) were added and the mixture was incubated at +4°C for 1 hour for 
preclearing. Ten % of the precleared protein from each sample was saved for 
confirming overexpression of ubiquilin-1 and FE65. The samples were centrifuged at 
8000 x g for 1 minute and the supernatant was mixed with anti-APP (A8717) antibody 
and rotated at +4°C for 1 hour. Fresh protein A/G agarose beads (Pierce) were added 
and the mixture was rotated at +4°C overnight to capture the coimmunoprecipitated 
proteins. The samples were centrifuged at 8000 x g for 1 minute. The beads were 
washed and precipitated proteins detached by heating at 95°C for 10 minutes in 30 µl 1x 
LDS loading buffer (Novex) containing 5% mercaptoethanol. The samples were 
centrifuged at 13000 x g for 15 minutes and supernatants were analysed using Western 
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blotting. Sample without antibody (beads only) was used as a negative control. 
Additionally, a sample with an antibody not interacting with APP (anti-myc) was used 
as a negative control. 
 
4.13 UPS REPORTER CELL EXPERIMENTS (STUDY III) 
 
HEK293T-UbG76V–YFP is a reporter cell line for detecting the function of UPS 
(Menendez-Benito V. et al., 2005). These HEK293T cells stably overexpress YFP-tagged 
ubiquitin with a G76V mutation. This UbG76V–YFP contains a ubiquitin fusion 
degradation (UFD) signal which targets it for proteasomal degradation. Global 
impairment of the proteasome in these cells results in an accumulation of proteins 
destined for proteasomal degradation including the UFD reporter substrate UbG76V–YFP. 
This leads to increased yellow fluorescence.  
 
HEK293T UbG76V-YFP cells transfected with myc-TV1-mRFP, myc-TV3-mRFP or mRFP 
were washed and fixed after 24 hours in 4% paraformaldehyde (PFA) and mounted in 
Mowiol (Mowiol 40-88, glycerol, Tris pH 8.5, DABCO). Cells were analysed using a 
wide-field fluorescence microscope (Leica DMI 6000B) with Hamamatsu C10600-10B 
(ORCA-R2) camera and X-Cite exacte mercury lamp. Images were quantified with 
Volocity Quantification software (Improvision). mRFP-positive cells were defined as 
objects with a minimum size of 50 µm2 and a minimal mRFP intensity of 300 AU and 
YFP intensity was quantified from these cells only. 
 
4.14 CONFOCAL MICROSCOPY (STUDY III, V) 
 
Cells were washed and fixed in 4% PFA or ice-cold acetone-methanol solution (1:1, used 
for the γ-tubulin staining). The cells were permeabilised and blocked for 30 minutes in 
PBS containing 0.1% Triton X-100 and 5% bovine serum albumin (BSA; Sigma). Cells 
were incubated with primary antibodies for 1.5 hours at the following dilutions: mouse 
anti-PS1 (MAB 5232, Chemicon) 1:400; mouse anti-vimentin (RV202, BD Pharmingen) 
1:50; and rabbit anti--tubulin (ab11317, Abcam) 1:5000. This was followed by 
incubation with secondary antibodies for one hour: Alexa Fluor® 488 goat anti-mouse 
(1:500, Molecular Probes), Alexa Fluor® 488 goat anti-rabbit (1:300, Molecular Probes), 
or goat anti-rabbit Cy5 (1:1000, Jackson ImmunoResearch Laboratories) antibody. 
Staining without primary antibodies was used as a negative control. Nuclei were 
stained with Hoechst 33342 at 1:5000 dilution (Sigma). Wide-field images were taken at 
40X magnification with Olympus BX40-FLA fluorescence microscope. Single optical z-
sections were obtained at 60X magnification using Nikon Eclipse-TE300 microscope and 
Ultra VIEW laser scanning confocal unit (PerkinElmer). Photomicrographs were 
processed using Adobe Photoshop software (Adobe Systems, USA).   
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4.15 ELECTRON MICROSCOPY (STUDY III) 
 
DAB-photoconversion: HEK293-AP-APP cells were transfected with PS1 and myc-TV1-
mRFP, myc-TV3-mRFP or control plasmid. Photoconversion method, as described by 
Meißlitzer-Ruppitsch et al., was used to visualize mRFP at the electron microscopic level 
(Meiblitzer-Ruppitsch C. et al., 2008). The cells were washed and fixed in 4% PFA for 30 
minutes, washed with 0.05 M Tris buffer, pH 7.4, and preincubated in 0.1% 3,3’-
diaminobenzidine (DAB; D5637, Sigma) for 30 minutes. Photoconversion was carried 
out under mercury lamp (100 W Ushio USH102D) until the fluorescence faded. The cells 
were then treated with 1% OsO4 (19130, EMS) and 1.5% potassium ferrocyanide 
(K4(Fe(CN)6) x 3H20, Merck) for 15 minutes followed by incubation in 1% OsO4. The 
cells were then prepared for transmission electron microscopy as described previously 
(Miettinen R. et al., 1991). Briefly, the cells were dehydrated and embedded in situ on the 
cell culture dishes. Beam capsules filled with LX-112 were laid upside down on the 
dishes and polymerized at 60°C for 48 hours. Ultrathin sections were cut on copper and 
nickel grids. 
 
Immunogold staining: Sections mounted on nickel grids were stained for myc using 
postembedding immunogold staining. Sections were treated with 1% periodic acid 
(30325, Riedel-de Haen) in ddH2O for 10 minutes followed by incubation in 3% sodium 
periodate (10259, BDH) in ddH2O 2 x 30 minutes. Sections were then incubated in 0.05 
M glycine (33226, Sigma) in PBS and then in PBS containing 5% BSA (A-2153, Sigma) 
and 0.1% cold water fish gelatine (G-7041, Sigma) to minimize unspecific binding. The 
sections were washed in 0.1% BSA-c (B2518, Sigma) in PBS and incubated in mouse 
anti-myc (1:100, 05-724, Upstate) overnight in a humid chamber. Sections were washed 
in BSA-c-PBS and incubated in 15 nm gold-conjugated anti-mouse (1:30, GAM, 815.022, 
Aurion) for 2 hours. The sections were washed and fixed in 2% glutaraldehyde (16220, 
EMS) and stained with uranyl acetate (02624-A, SPI-Chem) for 30 minutes and lead 
citrate (Ultrastain solution 2, 70553022, Leica) for 2 minutes. The sections were 
photographed using Jeol 1200 EX electron microscope. 
 
4.16 FLUORESCENCE LIFETIME IMAGING MICROSCOPY (FLIM) 
(STUDY III) 
 
Chinese hamster ovary (CHO) cells transfected with PS1 and V5-tagged TV1, TV2 and 
TV3 plasmids were double-immunostained with Cy3-labeled anti-PS1 C-terminus and 
Alexa430 fluorescently labeled anti-V5 antibodies (Hiltunen M. et al., 2006, Thomas A. 
V. et al., 2006). Forster resonance energy transfer (FRET) between the donor (Alexa 430) 
and acceptor (Cy3) fluorophores was assessed using TECAN FLT Ultraevolution 
system (Tecan Trading AG, Switzerland), and donor fluorophore lifetime and FRET 
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strength were monitored as measures of relative proximity between the PS1 C-terminus 
and ubiquilin-1-V5 and as a proportion of interacting molecules in each sample 
(Hiltunen M. et al., 2006, Thomas A. V. et al., 2006). 
 
4.17 STATISTICAL ANALYSES 
 
SPSS 14.0 software was used to perform single locus allele and genotype analyses. 
Haploview 4.1 program was used for pairwise linkage disequilibrium, Hardy-Weinberg 
equilibrium, haplotype as well as simulation analyses 
(http://www.broad.mit.edu/mpg/haploview/). nQuery Advisor Release 4.0 software 
was used to perform sample size and power determinations. Significant p-values were 
corrected for multiple testing by multiplying them with the number of studied SNPs 
(Bonferroni correction). In studies III and V, independent samples t-test, Mann-Whitney 
U-test or one-way analysis of variance (ANOVA) was used to test statistical significance 
between sample groups using SPSS program version 14.0. Values are indicated as mean 
± standard deviation (SD) or standard error of mean (SEM). The level of statistical 
significance was set to p < 0.05.  
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5. Results 
5.1 FREQUENCY OF APP DUPLICATIONS IN FINNISH EOAD PATIENTS 
(STUDY I) 
 
Previous studies have reported APP duplications in French and Dutch EOAD 
populations (Rovelet-Lecrux A. et al., 2006, Sleegers K. et al., 2006). Duplications in APP 
have since been reported also in Japanese patients and AD patients from the UK 
(Kasuga K. et al., 2009, McNaughton D. et al., 2010). We wanted to assess the frequency 
of APP duplications in a Finnish EOAD cohort. Our cohort consisted of 64 patients with 
30 familial EOAD and 34 sporadic EOAD samples. We used four DS samples and four 
healthy samples as controls in this study. All APP gene dosages were normalised to 
HBB. Both qPCR and qmPCR proved reliable methods to successfully detect duplication 
in DS samples in each analysis (Figure 6). This validation established both methods as 
being reliable for screening the patient samples. However, in our hands, qPCR gave 
more variation in results compared to qmPCR (Figure 6). Nevertheless, we consider 
both methods reliable for detecting gene dosage. Taken together, we did not find any 
APP gene duplications in our cohort of Finnish EOAD patients suggesting that APP 
gene duplications are rare in the Finnish EOAD patients.  
 
 
 
Figure 6: Graph showing APP gene dosages in two healthy control subjects and two Down’s 
syndrome (DS) patient samples using primers for APP 16i and Ex5 measured by qmPCR and 
qPCR (SD bars). Gene dosages are normalised to β-globin. Graphs show normal APP dosage 
for healthy subjects and 1.5-fold increase in APP gene dosage for DS patients.  
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5.2 ASSOCIATION BETWEEN GRN GENE POLYMORPHISMS AND AD IN 
FINNISH CASE-CONTROL COHORT (STUDY II) 
 
Mutations in the GRN gene are known to cause FTD. In this study, we wanted to assess 
the role of GRN in the susceptibility to AD. Our study population consisted of 512 
probable AD cases and 649 controls. We found the APOEε4 allele was significantly 
over-represented in the AD group compared to the control group (p < 0.001, OR = 4.5 
(95% CI 3.7-5.4). This was a validation confirming our case-control cohort as being 
normal. Genotyping of the SNPs rs850714, rs3785817, rs4792939, rs850713, rs5848, and 
rs850737 in the GRN gene (Figure 7) revealed two haplotype blocks (Table 6), one at the 
5’ end consisting of SNPs rs850714 and rs3785817 and a block at the 3’ end consisting of 
SNPs rs850713, rs5848, and rs850737 (Figure 7).  
 
Comparison of the allele and genotype distributions of the GRN SNPs did not reveal 
any significant differences between AD and control groups (Table 7). Also, the two 
individual haplotype blocks (block 1: rs850714-rs3785817 and block 2: rs850713-rs5848-
rs850737) did not reveal any significant associations.  
 
 
 
Figure 7. A schematic view of the GRN gene showing the location of SNPs used. 
Untranslated regions (UTRs) and coding exons (Ex) in GRN gene are indicated as grey and 
white boxes, respectively. 5' and 3' end regions of the GRN gene are not to scale (dashed 
line; Reprinted with permission from John Wiley and Sons).    
 
However, stratification of the population according to gender revealed significant allele 
and genotype associations with SNPs rs4792939, rs850713, rs5848 among men (Table 8). 
Furthermore, allele association of rs850713 and rs5848 remained significant even after 
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applying the Bonneferroni correction. Logistic regression analysis (age- and APOE-
adjusted multivariate analysis) revealed that SNPs rs850713 (TT + TC vs. CC, OR = 2.18, 
95% CI [1.37–3.48]) and rs5848 (AA + AG vs. GG, OR = 1.84, 95% CI [1.15–2.96]) 
conferred an approximately two-fold increase in risk for AD. 
 
Table 7. Allele and genotype frequencies of GRN SNPs among Finnish AD and control 
subjects. 
 
SNP Allele frequency Genotype frequency 
NCBI rs-
number and  
location (kb)a 
Allele Controls AD p-valueb Genotype Controls AD p-valueb
         
rs850714 (0)  n=1286 n=988   n=643 n=494  
 C 0.313 0.322 0.6378 CC 0.092 0.115 0.35 
 T 0.687 0.678  TC 0.442 0.413  
     TT 0.467 0.472  
         
rs3785817 
Intron 1 (6.1) 
 n=1266 n=932   n=633 n=466  
 T 0.648 0.651 0.8621 TT 0.409 0.406 0.82 
 C 0.352 0.349  TC 0.477 0.491  
     CC 0.114 0.103  
         
rs4792939 
Intron 1 (7.7) 
 n= 1282 n=1004   n= 641 n=502  
 A 0.808 0.837 0.0775 AA 0.654 0.701 0.21 
 G 0.192 0.163  AG 0.309 0.271  
     GG 0.037 0.028  
         
rs850713  
Intron 5 (10.1) 
 n=1280 n=1010   n=640 n=505  
 T 0.295 0.305 0.5887 TT 0.086 0.093 0.87 
 C 0.705 0.695  TC 0.417 0.424  
     CC 0.497 0.483  
         
rs5848  
UTR 3' (12.5) 
 n=1298 n=1012   n=649 n=506  
 G 0.642 0.622 0.3173 GG 0.411 0.381 0.58 
 A 0.358 0.378  AG 0.461 0.480  
     AA 0.128 0.138  
         
rs850737 (26)  n=1292 n=994   n=646 n=497  
 A 0.553 0.554 0.9356 GG 0.206 0.191 0.67 
 G 0.447 0.446  GA 0.483 0.509  
     AA 0.311 0.300  
 
aLocation of SNPs are indicated in 5' to 3' orientation with respect to SNP rs850714. 
bAllele and genotype frequencies were compared using two-sided Pearson’s 2 test. All the studied 
SNPs were in Hardy-Weinberg equilibrium in both cases and controls (p>0.05). 
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Table 8. Allele and genotype frequencies of GRN SNPs in men. 
 
SNP  Allele frequency Genotype frequency 
 Allele Controls AD p-valuea Genotype Controls AD p-valuea
         
rs850714  n=522 n=316   n=261 n=158  
 T 0.308 0.332 0.47 CC 0.88 0.108 0.75 
 C 0.692 0.668  TC 0.441 0.449  
     TT 0.471 0.443  
         
rs3785817   n=514 n=286   n=257 n=143  
 T 0.654 0.661 0.84 TT 0.416 0.420 0.94 
 C 0.346 0.339  TC 0.475 0.483  
     CC 0.109 0.098  
         
rs4792939   n=518 n=318   n=259 n=159  
 A 0.801 0.865 0.02 (0.12) AA 0.641 0.755 0.05 
(0.30) 
 G 0.199 0.135  AG 0.320 0.220  
     GG 0.039 0.025  
         
rs850713   n=520 n=314   n=260 n=157  
 T 0.267 0.354 0.009 (0.05) TT 0.088 0.115 0.02 
(0.12) 
 C 0.733 0.646  TC 0.358 0.478  
     CC 0.554 0.408  
         
rs5848   n=524 n=314   n=262 n=157  
 G 0.672 0.580 0.007 (0.04) GG 0.443 0.331 0.02 
(0.12) 
 A 0.328 0.420  AG 0.458 0.497  
     AA 0.099 0.172  
         
rs850737  n=520 n=314   n=260 n=157  
 G 0.425 0.481 0.12 GG 0.173 0.223 0.28 
 A 0.575 0.519  GA 0.504 0.516  
     AA 0.323 0.261  
 
aAllele and genotype frequencies were compared using two-sided Pearson’s 2 test. p-values were 
corrected for multiple testing using Bonferroni correction (corrected for six tests, in parenthesis). 
 
In summary, we did not find any significant genotype and allele associations between 
AD and control samples in the GRN SNPs. However, stratification according to gender 
revealed a significant allele and genotype association among men suggesting that GRN 
might affect susceptibility to AD in a gender-specific manner.  
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5.3 UBIQUILIN-1 AFFECTS PS1 ACCUMULATION (STUDY III) 
 
5.3.1 Ubiquilin-1 TV3 causes accumulation of PS1 into high-molecular-weight forms 
in HEK293-AP-APP cells 
 
Ubiquilin-1 is a PS1-interacting protein that has shown both genetic and functional 
association with AD (Mah A. L. et al., 2000, Massey L. K. et al., 2004, Massey L. K. et al., 
2005, Bertram L. et al., 2005, Hiltunen M. et al., 2006, Lu A. et al., 2009). Since previous 
studies have reported controversial data regarding the effects of ubiquilin-1 on -
secretase complex components, we wanted to characterize the effects of the four known 
ubiquilin-1 TVs on PS1 and the other -secretase complex components. TV1 and TV2 
overexpression in HEK293 cells stably overexpressing APP conjugated with alkaline 
phosphatase (HEK293-AP-APP) resulted in a significant increase in PS1-FL and PS1-
CTF levels compared to control cells. On the other hand, TV4 overexpression 
significantly reduced PS1-NTF levels. All four TVs caused an increase in PEN-2 levels 
(Study III, Figures 1B, 2A and 2B). However, it should be emphasised that these effects 
were moderate. The most striking finding was that TV3 consistently induced a 
prominent high-molecular-weight (HMW) smearing of PS1 above the PS1-FL band in 
the Western blot, suggesting PS1 accumulation (Study III, Figures 1B and 3B).  
 
Interestingly, we found that myc-TV3-mRFP overexpression in HEK293-AP-APP cells 
without PS1 overexpression failed to induce HMW-PS1 smearing in Western blot 
analysis. This held true also for H4 cells stably overexpressing TV3. These findings 
suggest that endogenous PS1 levels are not high enough to result in PS1 accumulation 
in TV3 overexpressing cells. One reason for this could be the high rate of PS-FL 
endoproteolysis into PS-NTF and PS-CTF taking place in cells (Wolfe M. S. et al., 1999). 
 
5.3.2 Ubiquilin-1 TV3 increases full-length PS1 stability in HEK293-AP-APP cells 
 
The HMW smear of PS1 in Western blots suggested that PS1 was accumulating. A 
cycloheximide time course experiment in HEK293-AP-APP cells overexpressing PS1 
and TV1, PS1 and TV3 or PS1 and control plasmid revealed that PS1 half-life was not 
significantly different between TV1 (2.8 ± 0.8 hours) and control samples (4.1 ± 0.7 
hours; Study III, Figure 3). However, TV3 overexpression significantly increased PS1 
half-life to 6.4 ± 1.4 hours (p = 0.017). This indicates that TV3 stabilises full-length PS1 by 
increasing PS1 half-life, which leads to PS1 accumulation. 
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5.3.3 Ubiquilin-1 TV3 does not affect the UPS in HEK293T-UbG76V–YFP cells 
 
We showed that TV3 stabilised full-length PS1 and induced accumulation of PS1 into 
HMW forms. We wanted to elucidate whether this was the result of a general 
impairment of the UPS. For this purpose we used HEK293T-UbG76V–YFP reporter cells. 
YFP intensities revealed no changes between cells overexpressing myc-TV1-mRFP and 
myc-TV3-mRFP indicating that the UPS was not grossly impaired (Study III, Figure 5A-
E). Treatment with the proteasomal inhibitor MG132 led to dramatic increase in YFP 
intensity in all samples, as expected. However, the MG132-treated samples also did not 
show any differences in YFP intensities between myc-TV1-mRFP and myc-TV3-mRFP 
cells. This suggests that the TV3-induced accumulation of PS1 is not the result of global 
UPS impairment. 
 
5.3.4 Ubiquilin-1 TV1 and TV3 enhance aggresome formation in HEK293-AP-APP 
cells 
 
A thorough microscopic investigation of PS1 and myc-TV1-mRFP or myc-TV3-mRFP 
overexpressing HEK293-AP-APP cells using fluorescence and confocal microscopy was 
performed (Study III, Figure 6A-C). In mRFP-transfected control cells, PS1 showed 
localisation on or close to the plasma membrane and in intracellular structures 
resembling ER and Golgi. There were no apparent differences in PS1 localisation 
between myc-TV1-mRFP- and myc-TV3-mRFP-transfected cells. However, these cells 
appeared to contain cytoplasmic aggresome-like inclusions more often than control 
cells. PS1 and myc-TV1-mRFP and myc-TV3-mRFP strongly colocalised in these 
inclusions. Stereological quantification of the number of cells containing the aggresomes 
revealed that ~42% of cells co-overexpressing PS1 and myc-TV3-mRFP and ~22% of the 
cells co-expressing PS1 with myc-TV1-mRFP contained aggresomes as compared to 
~11% in mRFP control cells (Study III, Figure 6D). The formation of aggresomes in TV1- 
or TV3-overexpressing cells was not the result of altered interaction with PS1 as 
revealed by high-throughput FLIM assay, which showed no significant differences in 
PS1 interaction between TV1 and TV3 (Study III, Table 1).  
 
Vimentin has been previously shown to redistribute to aggresomes and form a cage 
around the aggresomes (Olzmann J. A. et al., 2008, Kopito R. R., 2000). In mRFP control 
cells, vimentin was ubiquitously expressed and showed a strong localisation near the 
plasma membrane (Study III, Figure 7A-C). In contrast, in PS1- and myc-TV1-mRFP- or 
myc-TV3-mRFP-overexpressing cells, vimentin redistributed to aggresomes. Confocal 
microscopy revealed that vimentin formed a cage surrounding the myc-TV1-mRFP- or 
myc-TV3-mRFP-positive aggresomal core (Study III, Figure 8B). Aggresomal protein 
49 
 
aggregates are also known to be actively transported to the MTOC (Johnston J. A. et al., 
1998, Kopito R. R., 2000, Namekata K. et al., 2002), hence aggresomes typically colocalise 
with the MTOC marker γ-tubulin. We found that aggresomes colocalised with γ-
tubulin in cells co-expressing PS1 and myc-TV3-mRFP (Study III, Figure 9). These data 
confirmed that the observed inclusions indeed were aggresomes. Furthermore, our 
results suggest that aggresome formation was enhanced by overexpression of PS1 and 
myc-TV1-mRFP or myc-TV3-mRFP in HEK293-AP-APP cells. 
 
5.3.5 Ubiquilin-1 TV1 and TV3 enhance aggresome formation in neuronal cells 
 
We also examined aggresome formation in primary cortical cells from APP/PS1Δ9 mice 
(Jankowsky J. L. et al., 2001). The cells transfected with myc-TV1 or myc-TV3 did not 
show HMW-PS1 formation in Western blot analysis (Study III, Figure 10A). However, 
this could be due to low transfection efficiency in neurons. Our primary cultures were 
mixed cultures containing both neurons and glial cells. The transfection method used 
was found to transfect glial cells more efficiently than neurons. While biochemical 
analysis did not suggest that TV1 or TV3 would cause PS1 accumulation in primary 
cells, microscopy of the neurons revealed aggresome-like inclusions in neurons 
overexpressing myc-TV1-mRFP and myc-TV3-mRFP (Study III, Figure 10C and D). 
Interestingly, aggresomes were not found in glial cells. The aggresomes contained both 
PS1 and TV1 or TV3 and caused an indentation against the nucleus. Vimentin was 
robustly redistributed to the aggresomes similarly as that seen in HEK293-AP-APP cells 
(Study III, Figure S3).  
 
We also investigated aggresome formation in SH-SY5Y-APP751 cells. As with primary 
cells, Western blot did not show formation of HMW-PS1. However, by using 
microscopy we found increased formation of aggresomes in cells overexpressing PS1 
and myc-TV1-mRFP (~21%) or myc-TV3-mRFP (~25%) compared to cells expressing PS1 
and mRFP (~16%; Study III, Figure S4). However, aggresome formation was not evident 
in H4 neuroglioma cells overexpressing PS1 and myc-TV1-mRFP or myc-TV3-mRFP. 
These data agree with our findings in primary cell cultures where aggresomes were 
found only in neurons but not in glial cells. Overall, this points to cell-type specific 
differences whereby the aggresome pathway seems to be efficiently utilised by neurons 
and neuron-like cells and HEK cells, but not by cells of glial origin.  
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5.3.6 Ubiquilin-1 TV1 and TV3 affect Aβ levels but not γ-secretase activity 
 
One of the functions of the -secretase that is of principal importance in AD 
pathogenesis is to catalyse the production of Aβ. We found that Aβ40, Aβ42 and 
sAPPtot levels in the culture medium of HEK293-AP-APP cells transfected with TV1, 
TV2 or TV3, were significantly reduced (Study III, Figure 2C). We performed a -
secretase activity measurement in conditions of PS1 and TV1 or PS1 and TV3 
overexpression. There were no differences in -secretase activity between TV1 and TV3 
overexpressing samples indicating that the reduction in Aβ40 and Aβ42 was not due to 
altered -secretase activity (Study III, Figure 2D). However, interestingly, we found 
increased Aβ40 in culture media of myc-TV1-mRFP and myc-TV3-mRFP 
overexpressing primary neuronal cells and increased Aβ42 in myc-TV1-mRFP 
overexpressing primary neuronal cells (Study III, Figure 10B). Taken together, these 
results suggest that ubiquilin-1 TVs modulate -secretase complex component levels 
and Aβ and sAPPtot secretion, without affecting -secretase activity. Furthermore, these 
data suggest that aggresome formation does not affect γ-secretase activity in the studied 
cells. 
 
5.3.7 Electron microscopy confirms the presence of ubiquilin-1 TV1 and TV3 in 
aggresomes and autophagosomes 
 
HEK293-AP-APP cells transfected with PS1 and myc-TV1-mRFP or myc-TV3-mRFP 
were analysed at the electron microscopical level and found to contain dense 
amorphous aggregates (Study III, Figure 11). TV3-transfected cells contained more 
aggregates than TV1 cells. These aggregates were either dispersed in the cytoplasm or 
found within autophagosomes. The cells contained high number of mitochondria, 
autophagic vacuoles and secondary and late lysosomes. The cells also typically 
contained large multilamellar-multivesicular inclusions composed of double-
membranes wrapping several times around inclusion bodies. Bundles of intermediate 
filaments could also be identified in the vicinity of the inclusions or aggresomes.  
 
DAB photoconversion method was used to view mRFP signal originating from the tags 
in myc-TV1-mRFP or myc-TV3-mRFP. The DAB precipitates appeared to be mainly 
located in the membranes forming the autophagic vacuoles. Multilamellar-
multivesicular inclusions were found near the nucleus. Staining for myc using 
immunogold revealed highly concentrated myc staining in aggresomes wrapped inside 
autophagosomes. These data confirm light and confocal microscopical data that TV1 
and TV3 localise in aggresomes and further imply that the aggresomes might be 
targeted to autophagosomes. 
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5.4 EFFECTS OF UBIQUILIN-1 ON APP PROCESSING AND THE γ-
SECRETASE (STUDY V) 
 
We have previously shown that ubiquilin-1 is genetically associated with AD, and the 
ratio of TV1 vs. TV2 mRNA levels was found to be altered in brain tissue of AD patients 
(Bertram L. et al., 2005). Furthermore, our functional studies of ubiquilin-1 
downregulation in H4 and HEK293 cells showed modulation of APP holoprotein and 
APP-CTF levels as well as Aβ secretion (Hiltunen M. et al., 2006). Therefore, it is 
important to assess the functional relevance of the ubiquilin TVs in the molecular 
pathogenesis pathways of AD. In this study, we assessed the effects of overexpression 
of ubiquilin-1 full-length TV1 and the AD-associated TV2 in SH-SY5Y-APP751 cells.  
 
5.4.1 Overexpression of ubiquilin-1 TV1 increases APP-CTF production and affects 
APP maturation in SH-SY5Y-APP751 cells 
 
We found that TV1 overexpression significantly increased the ratio between APPm and 
APPim without affecting APP holoprotein levels (Study V, Figure 1A). The APP-CTF 
C83 and C99 levels were also significantly increased with the C99 increase being more 
prominent. Longer exposure of the blot also revealed AICD bands in the TV1-
overexpressing samples. TV1 overexpression in SH-SY5Y cells stably overexpressing 
APP751 (SH-SY5Y-APP751) did not change sAPPα levels but significantly increased 
sAPPtot levels (Study V, Figure 1B). There was also a trend towards an increase in Aβ40 
and Aβ42 levels compared to control cells. We also overexpressed TV1 in SH-SY5Y cells 
stably overexpressing myc-tagged BACE1 (SH-SY5Y-BACE1-myc). In these cells, TV1 
overexpression caused a prominent increase in β-CTF levels (C89 + C99) similar to the 
APP-CTF increase observed in SH-SY5Y-APP751 cells (Study V, Figure 1C). There were 
no changes in the BACE1 protein levels. Contrary to SH-SY5Y-APP751 cells, assessment 
of these parameters from H4 cells stably overexpressing TV1 showed a significant 
decrease in C83 levels with no changes in APP maturation and C99 levels. However, 
these results are in line with our previous findings of downregulation of TV1 in H4 cells 
where the C83 levels were increased instead (Hiltunen M. et al., 2006). Taken together, 
these data indicate that overexpression of TV1 in SH-SY5Y-APP751 and SH-SY5Y-
BACE1-myc cells promoted APP maturation, increased APP-CTF production and 
sAPPtot levels, and that the effects might be different in neuronal and non-neuronal 
cells. 
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5.4.2 Overexpression of TV1 increases ICD production from two different γ-secretase 
substrates without affecting the γ-secretase complex component levels in SH-SY5Y-
APP751 cells 
 
To follow up on our initial finding of increased levels of AICD in TV1-overexpressing 
samples, we employed an in vitro AICD generation assay. We found that TV1 
overexpressing samples consistently showed a 1.5-fold increase in C83-normalised 
AICD generation compared to control cells (Study V, Figure 2A). These findings 
suggest that TV1 increases AICD generation in SH-SY5Y-APP751 cells by enhancing γ-
secretase mediated ε-cleavage of APP-CTFs.  
 
To investigate whether this effect was specific for APP only, we tested whether TV1 
increased ICD generation from another γ-secretase substrate, LAR receptor tyrosine 
phosphatase. In cells co-expressing TV1 and LAR, LAR-ICD (LICD) levels normalised 
to LAR-CTF levels were increased (Study V, Figure 2B). However, in the same samples 
the AICD levels were similar to control samples. These findings imply substrate 
competition between APP and LAR for γ-secretase-mediated cleavage and that TV1 
overexpression leads to a γ-secretase preference for LAR over APP.  
 
We next assessed the γ-secretase compex component levels, namely PS1-CTF, PS1-NTF, 
PEN-2, APH1A and NCT, in cells overexpressing TV1 and PS1 (Study V, Figure 3). We 
found no major changes except in the case of PS1-NTF whose levels were significantly 
increased. In cells overexpressing only TV1 and not PS1, the endogenous PS1-CTF and 
NTF levels and NCT levels were unchanged. These data indicate that the TV1-induced 
increase in AICD and LICD generation was not due to increased γ-secretase complex 
component levels. Altogether, these data suggest that TV1 modulates γ-secretase 
function, specifically the γ-secretase mediated ε-cleavage without affecting the γ-
secretase complex component levels.  
 
Since the majority of the AICD generation has been shown to take place at or close to 
the plasma membrane and/or in early endosomes (Kaether C. et al., 2006b), we wanted 
to investigate whether the increased AICD generation in TV1 overexpressing cells was 
due to increased APP trafficking to the plasma membrane. Surface biotinylation 
experiment indicated no differences in the cell surface levels of APPm in TV1 
overexpressing cells compared to control cells (Study V, Figure 4). Additionally, we also 
examined cell surface levels of NCT and found no differences between TV1 
overexpressing cells and control cells. NCT is one of the four components of the γ-
secretase complex that is believed to be necessary for efficient γ-secretase activity. NCT 
levels on the cell surface can be used as a surrogate for the γ-secretase complex levels 
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on the cell surface. These results suggest that TV1 overexpression does not lead to 
changes in levels of APPm or the γ-secretase complex at the plasma membrane. 
 
5.4.3 Overexpression of FE65 leads to reduced levels of APPim in SH-SY5Y-APP751 
cells 
 
FE65, an APP adaptor protein, has been shown to stimulate the production of and to 
interact with AICD, and stabilise its levels. It has also been shown to be involved in 
AICD-mediated signalling and gene transcription (Wiley J. C. et al., 2007, Ma Q. H. et al., 
2008). Therefore, we wanted to investigate whether the increased AICD levels in TV1-
overexpressing cells were mediated through FE65. We found that endogenous and 
exogenous FE65 levels were consistently increased in the presence of TV1 although this 
increase was not statistically significant (Study V, Figure 5). FE65 interaction and 
binding to APP can be modulated by phosphorylation of APP at the threonine residue 
at position 668 (Thr668; Ando K. et al., 2001).  Interestingly, levels of APP 
phosphorylated at Thr668 also showed a similar pattern of increase as FE65 in the 
presence of TV1 overexpression. Furthermore, FE65 overexpression alone or together 
with TV1 significantly reduced levels of APPim leading to an increased APPm/APPim 
ratio. Importantly, APP-CTF C83 and C99 levels were unaffected by FE65 
overexpression. On the contrary, FE65 appeared to abolish APP-CTF increase caused by 
TV1 overexpression alone. Hence, the FE65 overexpression phenotype is different 
compared to TV1 overexpression in terms of APP processing.  
 
The binding of both TV1 and FE65 to APP takes place at the APP C-terminus. Hence, 
we hypothesised that TV1 and FE65 would compete for APP binding when co-
overexpressed. We found no differences in the amount of APP coimmunoprecipitating 
with FE65 with or without TV1 overexpression suggesting that our findings of TV1-
induced increase in APP-CTFs and AICD levels is not mediated by FE65 (Study V, 
Figure 6). 
 
5.4.4 Overexpression of ubiquilin-1 TV2 affects APP-CTF and AICD production 
differently compared to TV1 in SH-SY5Y-APP751 cells 
 
Next, we wanted to study the effects of the AD-associated ubiquilin-1 TV2 on APP 
processing and maturation. Myc-TV1 overexpression led to increased levels of APP-
CTFs C83 and C99 and a slight but non-significant increase in Aβ40 and Aβ42 levels, 
similar to what was seen with untagged TV1 (Study V, Figure 7A and B). Myc-TV2 
overexpression also resulted in increased C83 and C99 levels, but less pronounced than 
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TV1. Also, Aβ40 and Aβ42 levels were similarly slightly increased (Study V, Figure 7C). 
These results indicate that TV1 and TV2 exert similar effects. However, myc-TV2 did 
not cause increased AICD generation, as seen robustly in TV1 overexpressing cells 
(Study V, Figure 8). This suggests that TV2 modulation of APP processing is different 
from TV1. Furthermore, TV2 does not appear to modulate the γ-secretase in a similar 
manner as TV1. 
 
To elucidate the mechanism behind these differences between TV1 and TV2, we 
performed FLIM assay to study the interaction between TV1 and TV2 and PS1. We 
found no significant differences between the proximity of either TV1 or TV2 and PS1, 
ruling out differential PS1 interaction as a possible mechanism behind the dissimilar 
effects of TVs on γ-secretase function (Study V, Table 1). Furthermore, there were no 
changes in the subcellular localisation of APP between TV1 and TV2 overexpressing 
cells. APP localised in intracellular compartments and at the plasma membrane in cells 
expressing TV1 and TV2 and there were no differences between these cells and control 
cells in APP localisation (Study V, Figure 9). Hence, TV1 and TV2 do not alter the 
subcellular localisation of APP. 
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6. Discussion 
6.1 LOW PREVALENCE OF APP DUPLICATIONS IN FINNISH EOAD 
PATIENTS 
 
We screened a total of 141 Swedish and Finnish EOAD samples but found no APP 
duplications in the cohort. Similar studies in a Dutch EOAD population found the 
frequency to be 2.7% while in a French population the APP duplication frequency was 
much higher at 8% (Rovelet-Lecrux A. et al., 2006, Sleegers K. et al., 2006). However, 
based on our results, the frequency seems to be much lower in Swedish and Finnish 
EOAD patients. Given the frequencies in the French and Dutch studies, one would have 
expected to find 2-5 patients with APP duplications among our EOAD patients. The 
difference between these populations could be due to segregation of such genetic 
phenomena in a population-dependent manner. Since DS patients have a trisomy of 
chromosome 21, which is where the APP gene locus is located, DS patient samples may 
be used as a positive control for APP duplications. We used four DS samples and four 
healthy samples as controls in this study. The two methods used, qPCR and qmPCR, 
proved reliable, as both successfully detected the duplication in DS samples in every 
analysis. However, in our hands, qmPCR appeared to be less variable than qPCR. This 
could be perhaps due to the fact that all the primers were pooled together, giving a 
more even comparison of gene dosage for each sample. Nevertheless, we consider both 
methods valid for gene dosage screening studies.  
 
DS patients develop dementia that resembles AD by the 4th decade of their lives (Oyama 
F. et al., 1994). These findings imply that apart from the familial mutations that increase 
production of Aβ, also an increase in the gene dosage of APP per se can lead to the onset 
of AD. This provides further support to the amyloid cascade hypothesis according to 
which Aβ deposition triggers the cascade of events leading to dementia and AD onset 
(Hardy J. et al., 1991). The duplication cases in the French study by Rovelet-Lecrux et al. 
presented symptoms of dementia as well as CAA in the absence of a complete 
duplication of the chromosome. This demonstrates that a duplication of the APP gene 
alone is enough to cause AD dementia, further supporting the role of Aβ as one of the 
primary instigators in the pathological cascade leading to dementia.  
 
Also, in a Finnish family suffering from intracerebral haemorrhages and cognitive 
decline, APP duplications were reported (Rovelet-Lecrux A. et al., 2007). However, one 
rare case of DS with partial trisomy of chromosome 21 distal to the APP gene resulted in 
no neuropsychological or neuropathological signs of AD. The region of duplication can 
be variable resulting in a variable phenotype presented in the individuals, ranging 
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between complete absence of dementia, dementia, CAA and intracerebral 
haemorrhages.  
 
Even in the absence of APP duplications, the mRNA levels of APP are increased 
approximately three-fold in the nucleus basalis of Meynert, Brodmann area 21, and 
locus coeruleus in AD brains compared to controls (Cohen M. L. et al., 1988, Palmert M. 
R. et al., 1988). Furthermore, levels of APP containing the KPI domain are increased in 
AD brains and in a mouse model of AD (overexpressing APP V717F; Games D. et al., 
1995, Moir R. D. et al., 1998, Tanaka S. et al., 1989). This increase drives amyloidosis 
further and is at least partly mediated by changes in the APP gene transcription. 
However, it is worthwhile to mention that conflicting findings of increase in levels of 
APP not containing the KPI domain have been found in human AD brains (Johnson S. 
A. et al., 1988). Nevertheless, perturbation of APP mRNA and protein levels have been 
found over the decades in AD brains resulting from the presence or absence of APP 
gene duplications.  
 
6.2 GENETIC VARIABILITY IN GRN MAY INCREASE RISK OF AD IN 
MALES 
 
GRN has been suggested to be a possible biomarker for FTD dementia as significantly 
reduced plasma levels have been shown to predict mutation status in patients (Finch N. 
et al., 2009). Functions of PGRN include immunomodulation in inflammation and 
wound healing and involvement in neurodegeneration and in traumatic brain injury. 
PGRN also has neurotrophic properties (He Z. et al., 2003, Baker M. et al., 2006, Cruts M. 
et al., 2006, Van Damme P. et al., 2008). Since these pathways are also relevant in AD 
pathogenesis and since it is possible that variations in GRN gene could affect 
susceptibility to AD, we elucidated whether variability in GRN affects risk of AD.  
 
We did not find any association in the whole AD-control cohort. However, SNPs 
rs4792939, rs850713, and rs5848 were associated in male AD patients suggesting that 
GRN might increase susceptibility for AD in a gender-specific manner. Our haplotype-
based association analysis showed a haplotype T-A-G (SNPs rs850713-rs5848-rs850737) 
which is also over-represented among men. It is possible that this gender-specificity is 
linked to sex hormones. In mammals, sexual differentiation of the brain occurs 
independently of the genetic composition of the foetus. Rather, it results from androgen 
stimulation of androgen receptors (Suzuki M. et al., 2002). Developmental studies have 
shown that GRN expression remains high in male foetuses, while it gradually reduces 
in female foetuses (Suzuki M. et al., 1998). Further, GRN has been shown to play a key 
role in the masculinisation of the male rat brain (Suzuki M. et al., 2000). This could 
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indicate that alterations in GRN levels due to certain genotypes could affect 
susceptibility to neurodegeneration in a sex-dependent manner. More studies are 
required to assess the specific role of GRN in adult men.  
 
Similar to our findings, it was shown that a haplotype consisting of allele A for rs850713 
and allele T for rs5848 was also over-represented among Belgian AD patients (Brouwers 
N. et al., 2008). These findings suggest that genetic variations at the 3’ end of GRN may 
increase the risk of AD. The same year, Rademakers et al. found that homozygous 
carriers of the T allele at SNP rs5848 had a 3.2-fold increased risk for developing FTDU 
(Rademakers R. et al., 2008). They reported that SNP rs5848 is located in a predicted 
miRNA-binding site for miR-695. miRNAs are, on average, 22 nucleotide long 
molecules that bind to complementary target mRNA molecules, leading to degradation 
of the target mRNA strand. In this way, they can mediate translational repression and 
gene silencing (Bartel D. P. 2009, Bartel D. P. 2004). miR-695 binding significantly 
decreased PGRN levels, but not GRN mRNA levels, in TT carriers compared to CC 
carriers. This indicated that mRNA containing the T-allele could bind miR-695 more 
tightly, leading to increased silencing and hence haploinsufficiency, mimicking the loss-
of-function caused by mutations in familial cases. Hence, polymorphisms in SNPs can 
regulate miRNA binding efficiency, thereby modulating protein levels.  
 
Another miRNA which targets GRN is miR-107. miR-107 has been shown to be 
downregulated early in AD (Wang W. X. et al., 2010). It is also epigenetically repressed 
in cancers such as lung adenocarcinomas, substantially increasing PGRN levels which 
potentiates tumour growth. Studies have shown that miR-107 is relevant in glucose 
metabolism in cell cultures. Furthermore, there appears to be an inverse correlation 
between miR-107 and PGRN levels in traumatic brain injury mouse model where the 
injury site shows reduced miR-107 level and increased PGRN protein levels. These 
findings suggest that miRNAs may also play a key role in susceptibility to 
neurodegenerative diseases.  
 
6.3 ROLE OF UBIQUILIN-1 IN PROTEIN AGGREGATION 
 
Ubiquilin-1 is an important protein mediating protein aggregation (Massey L. K. et al., 
2004, Massey L. K. et al., 2005). Ubiquilin-1 is known to interact with proteins using its 
UBA domain. These proteins include PS1 and PS2 (Mah A. L. et al., 2000, Massey L. K. et 
al., 2005, Hiltunen M. et al., 2006, Thomas A. V. et al., 2006, Ford D. L. et al., 2007) which 
contain the catalytic site of the γ-secretase complex catalysing the release of the Aβ 
peptide. Hence, ubiquilin-1-PS interaction is one of special importance in AD. Studies 
have shown that ubiquilin-1 promotes accumulation of PS and modulates the levels of 
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γ-secretase complex components (Mah A. L. et al., 2000, Massey L. K. et al., 2005). 
However, the effects of specific ubiquilin-1 TVs on PS1 have not been studied 
previously. In our study, we dissected the effects of the different ubiquilin-1 TVs on the 
aforementioned parameters in HEK293-AP-APP cells over-expressing PS1 together with 
the TVs. Our initial findings revealed that different TVs affected the γ-secretase 
complex components differentially, in particular PS1-FL, PS1-CTF and PEN-2 levels, but 
these effects were fairly modest. However, the most notable effect was the prominent 
accumulation of PS1 specifically in TV3-overexpressing cells. The accumulated PS1 
appeared as a HMW smear in Western blot analysis of TV3-expressing cells. 
Interestingly, PS1 also accumulated in TV1-expressing cells, as juxtanuclear aggresomal 
structures containing PS1 were found in both TV1- and TV3-overexpressing cells, as 
assessed by microscopy. TV1 overexpression resulted in significantly reduced Aβ42 
levels while TV3 overexpression led to significantly reduced Aβ40, Aβ42 and sAPPtot 
levels. These findings agree with our previous data showing that TV1 downregulation 
in the same cells increased Aβ and sAPP levels as a result of altered APP trafficking 
(Hiltunen M. et al., 2006). The γ-secretase activity was unchanged in cells 
overexpressing TV1 and TV3. These findings together provide evidence that aggresome 
formation in PS1- and TV1- or TV3-expressing cells does not directly affect γ-secretase 
activity and that alterations in Aβ levels were the result of altered APP trafficking. 
 
In contrast to HEK293-AP-APP cells, the Aβ levels in primary cortical cell cultures were 
significantly increased upon TV1 and TV3 overexpression. Previous studies have shown 
similar findings where TV1 overexpression in human neuroblastoma SH-SY5Y cells also 
causes an increase in AICD and sAPP levels (Zhang C. et al., 2007). Our primary 
neuronal cultures were mixed cultures containing both glial cells as well as neurons. 
While we did not see the PS1 HMW smear in Western blot analysis of these cultures, 
microscopy revealed the presence of aggresomes in neurons but not astrocytes. Our 
transfection method resulted in higher transfection efficiency among glial cells than in 
neurons. Since we found aggresome formation only in neurons and not in astrocytes, 
this could explain the absence of the HMW-PS1 smear in Western blots. In line with 
these observations, we did not find aggresomes in human neuroglioma H4 cells, further 
indicating a propensity for aggresome formation in neuronal and neuron-like cells as 
opposed to cells of glial origin. However, the low transfection efficiency among neurons 
raises the possibility that the increase in Aβ levels could have a glial contribution as 
well. Aβ is believed to be primarily produced by neurons, which holds especially true 
in cultures such as ours where neurons overexpress APP. Furthermore, PS1 staining of 
these cultures showed PS1 localisation mostly in neurons with weak staining in glial 
cells. These factors indicate that the Aβ measured by the human-specific ELISA kit was 
predominantly produced by neurons. Collectively, these findings emphasise that effects 
of ubiquilin-1 may depend on the cell-type studied, since APP maturation, processing 
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and Aβ secretion are different in different cells, especially when comparing neuronal 
and non-neuronal cell lines. In this context, it should be noted that future studies in 
primary neuronal cultures should utilise lentiviral-based transductions of ubiquilin-1 
constructs to increase neuron-specific expression of ubiquilin-1 TVs.  
 
It is interesting to note that aggresome formation did not coincide with altered γ-
secretase activity. It is known that the levels of PS1 in the γ-secretase complex are 
tightly regulated (Thinakaran G. et al., 1997). In aggresome containing cells, PS1 was 
localised not only in the the aggresome core but also on the plasma membrane. One 
implication of this finding could be that the levels of PS1 on the plasma membrane are 
sufficient to maintain normal levels of γ-secretase activity. However, while the 
aggresome formation did not affect γ-secretase activity, it cannot be ruled out that PS1 
sequestration into aggresomes could affect other PS1-dependent cellular functions.  
 
Ubiquilin-1 is a ubiquitin-like protein containing the characteristic UBA and UBL 
domains for binding poly-ubiquitinated proteins and the proteasome, respectively. In 
this way, ubiquilin-1 acts as a link between proteins destined for proteasomal 
degradation and the proteasome. TV1 is the full-length TV and contains all 11 exons, 
while TV3 lacks exons 2, 3 and 4 (Lu A. et al., 2009). Both TV1 and TV3 contain intact 
UBA domains, and our FLIM experiments indicated that there were no differences in 
their interaction with PS1. However, TV3 lacks most of the UBL domain making it less 
efficient in interacting with the proteasome. Our results suggest that this challenged 
ability to interact with the proteasome is the most likely explanation for the prominent 
accumulation of PS1. As a consequence, aggresome formation is seen in TV3 
overexpressing cells (Figure 8). Further evidence for this comes from our results 
showing no impairment of the UPS in TV1- or TV3-overexpressing cells. Instead, the 
PS1-FL half-life is increased in TV3 overexpressing cells compared to TV1 indicating 
that PS1-FL forms are stabilised by TV3 as a result of inefficient proteasomal 
degradation. Also, the aggregated PS1-FL may not be a suitable target for proteasomal 
degradation. As the four known ubiquilin-1 TVs are present in the human brain 
(Bertram L. et al., 2005, Lu A. et al., 2009), ubiquilin-1 splicing may vary as a result of age 
or pathological conditions, in turn determining the propensity of neurons to form 
aggresomes. TV1 and TV3 overexpression altered Aβ and sAPP levels, which could 
have further effects on neuronal survival. PS1 sequestration in aggresomes and 
increased PS1-FL half-life did not affect γ-secretase activity but could affect other PS1-
related functions affecting cells in different ways.   
 
Apart from PS1, ubiquilin-1 also enhances aggresome formation in a poly-glutamine 
disease model reminiscent of HD. This is mediated by its interaction with epidermal 
growth factor substrate 15 (EPS15) via the UBA domain. While TV3 lacks most of the 
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UBL domain, the remaining N-terminal portion of the UBA domain might be sufficient 
to enable EPS15 binding and aggresome formation. Furthermore, ubiquilin-1 regulates 
aggregation of, and coaggregates with, 43-kDa TAR DNA-binding domain protein 
(TDP-43), a key protein in the pathogenesis of FTD and amyotropic lateral sclerosis 
(Heir R. et al., 2006, Kim S. H. et al., 2009). However, as opposed to EPS15, TDP-43 
interacts with the UBA domain of ubiquilin-1. Subsequently, the ubiquilin-1 TV lacking 
the UBA domain was ubable to mediate TDP-43 aggregation. These data implicate 
ubiquilin-1 in proteasomal degradation and aggresome formation in other 
neurodegenerative diseases and AD.  
 
According to current hypotheses, aggresome formation is a cytoprotective phenomenon 
whereby the cell sequesters potentially harmful aggregates of proteins into temporary 
harmless structures, which can then be cleared by autophagy (Olzmann J. A. et al., 2008, 
Kopito R. R., 2000). Similar hypotheses have been put forward in the context of PD 
where Lewy bodies are suggested to be neuroprotective against dopaminergic toxicity 
(Au W. L. et al., 2005). Also in AD, amyloid plaques are considered less harmful when 
compared to oligomers of Aβ (Naslund J. et al., 2000, McLean C. A. et al., 1999, Lue L. F. 
et al., 1999, Larson J. et al., 1999, Moechars D. et al., 1999, Hsia A. Y. et al., 1999, Mucke L. 
et al., 2000, Dodart J. C. et al., 2002). The fact that aggresome formation was seen in 
primary neurons overexpressing TV3 shows that this process of protein accumulation is 
not limited to non-neuronal cells, but is a global phenomenon used by various types of 
cells. On the other hand, our results indicated that cells of glial type may not form 
aggresomes, at least under conditions investigated here. Our data also suggest that 
aggresomes are targeted for autophagosomal/autolysosomal degradation, reinforcing 
the notion that aggresomes might function as a temporary storage to sequester harmful 
protein aggregates that are later degraded by autophagic mechanisms. In accordance 
with this, studies have reported that ubiquilin-1 interacts with mTOR, which is an 
inhibitor of autophagy. This results in mTOR inhibition, induction of autophagy and a 
reduction in toxicity caused by harmful protein aggregates (Wu S. et al., 2002, 
Ravikumar B. et al., 2004). Furthermore, ubiquilin-1 and 2 have been shown to associate 
with autophagosomes and mediate cell survival during nutrient starvation via this 
interaction (N'Diaye E. N. et al., 2009). Our results also show that aggresomes are 
formed only when PS1 is co-overexpressed with TV1 or TV3. These findings suggest 
that specific conditions of excess in protein levels, and specifc interaction of the 
accumulated protein and TV1 or TV3, are required to instigate aggresome formation. 
Other triggers, such as proteasomal inhibition and heat shock (Johnston J. A. et al., 1998, 
Kovacs I. et al., 2006), have also been shown to instigate formation of PS1-containing 
aggresomes. However, our data indicated that proteasomal function was not impaired 
in TV1- or TV3-expressing cells and thus it was not the underlying mechanism in 
aggresome formation in our system. 
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6.4 ROLE OF UBIQUILIN-1 IN APP MATURATION AND PROCESSING 
 
Ubiquilin-1 has been reported to modulate APP maturation and trafficking in various 
cell lines (Hiltunen M. et al., 2006, Zhang C. et al., 2007). In this study, we wanted to 
examine the effects of ubiquilin-1 TVs on APP processing and clarify the underlying 
molecular mechanisms behind these effects. We found that transient overexpression of 
two ubiquilin-1 TVs, full-length TV1 and AD-associated TV2, exert differential effects 
on APP maturation and processing in SH-SY5Y-APP751 cells. TV1 overexpression 
significantly increased APPm/APPim ratio and C83 and C99 levels, and the effect on 
C99 levels was more pronounced. This was coupled with elevated sAPPtot and AICD 
levels, suggesting that APP maturation and processing were enhanced. It is conceivable 
that the C83 levels were not as strongly increased as those of C99 because C83 
fragments are the preferred substrate for AICD generation (Kume H. et al., 2004). These 
data are consistent with findings in the SH-SY5Y-APP-Gal4 cell line (Zhang C. et al., 
2007). In contrast, when we overexpressed TV1 in H4 cells, we found significantly 
decreased C83 levels. These findings agree with those described previously in HEK293 
and H4 cells (Hiltunen M. et al., 2006). Ubiquilin-1 has also been studied in D. 
melanogaster. Overexpression of the fly orthologue of ubiquilin-1 led to decreased levels 
of APP, C83 and C99 (Li A. et al., 2007). However, opposite results were reported upon 
ubiquilin-1 knockdown in transgenic flies overexpressing C99-Gal4 construct where 
APP and APP-CTF levels were decreased (Gross G. G. et al., 2008). Taken together, these 
data suggest that the effects of ubiquilin-1 on APP maturation and processing are 
dependent on the cell type, as these processes appear to differ between neuronal and 
non-neuronal cell lines. Studying different cell types provides information on the 
different molecular mechanisms existent in these cells and is useful in furthering our 
understanding of protein functions.  
 
The second ubiquilin-1 TV studied was TV2, which lacks exon 8. TV2 has been shown 
to be especially relevant in AD as TV2 mRNA levels were found to be increased in AD 
brains as compared to controls (Bertram L. et al., 2005). Our study is the first to report 
the effects of TV2 on APP trafficking and processing. We found that TV2 
overexpression in SH-SY5Y-APP751 cells does not affect APP maturation, but it 
significantly increases C83 and C99 levels. However, this increase in the APP-CTF levels 
is less prominent when compared to TV1-expressing cells.   
 
Both TV1 and TV2 overexpression resulted in a slight trend towards an increase in 
Aβ40 and Aβ42 levels which was not statistically significant. Similarly, we found that 
TV1 overexpression in cultured primary cortical cells from APP/PS1Δ9 mice resulted in 
significantly increased Aβ40 and Aβ42 levels.  
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In summary, ubiquilin-1 TV1 and TV3 affect APP maturation and processing 
differentially in neuronal and non-neuronal cells (Figure 9).  
 
6.5 ROLE OF UBIQUILIN-1 IN γ-SECRETASE MODULATION 
 
One of the most prominent effects of TV1 overexpression in SH-SY5Y-APP751 cells was 
a robust increase in AICD levels. However, this was not coupled with significantly 
increased Aβ levels. We hypothesised that this might be the result of increased stability 
of the AICD fragment itself. In this regard, we concentrated on FE65, an APP adaptor 
protein, shown to stabilize AICD and aid in AICD-mediated gene transcription 
(Kimberly W. T. et al., 2001, Cao X. et al., 2001). However, the FE65 overexpression 
phenotype is contradictory to that of TV1 overexpression. FE65 overexpression 
decreased APP maturation in SH-SY5Y-APP751 cells and had no effect on APP-CTF 
production. There was also no difference in the amount of APP interacting with FE65 
with or without TV1 overexpression. These findings rule out FE65 as a possible 
mediator of the TV1-induced increase in AICD levels. 
 
Next, we investigated the γ-secretase complex itself. However, we did not find any 
changes in the levels of the four components of the γ-secretase complex in TV1-
overexpressing cells. Also, the levels of NCT at the plasma membrane were unchanged 
upon TV1 overexpression. Since NCT is suggested to be required for a functional γ-
secretase, this finding implies that the levels of functional γ-secretase are also 
unchanged at the plasma membrane. However, while NCT may be necessary for the γ-
secretase activity and stability, a recent study has reported the existence of a γ-secretase 
complex lacking NCT (Zhao G. et al., 2010). This PS1/PEN-2/APH1A γ-secretase 
complex was shown to be functional although it is highly unstable and only displays 
50% of the activity of the γ-secretase containing NCT. Nevertheless, all these data point 
to a direct modulation of the γ-secretase activity itself as one of the likeliest 
explanations for these results (Figure 9). 
 
An increase in the AICD generation without an increased Aβ production suggests that 
TV1 overexpression specifically causes an increase in the ε-cleavage which releases 
AICD, while the γ-cleavage generating Aβ remains unaffected. The γ-secretase is a 
promiscuous enzyme complex known to mediate at least three known 
intramembranous cleavages in APP namely ε-, γ- and ζ-cleavages. The cleavages occur 
sequentially with ε-cleavage taking place between residues 49 and 50 first, followed by 
the γ-cleavage releasing Aβ40 or 42. However, while both ε- and γ-cleavages are PS1-
dependent, they can be differentially regulated. Some mutations in PSEN1 gene inhibit 
ε-cleavage while promoting the γ-cleavage. As a result, Aβ production, most 
64 
 
prominently that of Aβ42, is increased (Chen F. et al., 2002). Since the γ-secretase 
produces Aβ, it has been a central target for therapeutic interventions. Some γ-secretase 
inhibitors reduce Aβ production without affecting the ε-cleavage-mediated AICD 
production (Petit A. et al., 2001). There are also endogenous PS1-interacting proteins 
such as TMP21, which affect γ-secretase selectively by modulating the γ-cleavage but 
not the ε-cleavage (Chen F. et al., 2006). As ubiquilin-1 is also a PS-interacting protein, it 
is highly possible that it too selectively affects the ε-cleavage without altering the γ-
cleavage.  
 
On the other hand, TV2 which does not increase APP-CTF levels as robustly as TV1, 
does not increase AICD generation. It is conceivable that these differences are the result 
of structural differences between the two TVs. While TV1 is the full-length TV 
containing all 11 exons, TV2 lacks exon 8 adjacent to the UBA domain. This could imply 
that conformational differences between TV1 and TV2 result in differences in the 
interaction with APP and/or PS1. However, this possibility is invalidated by our FLIM 
data suggesting that there are no differences in TV1 and TV2 interaction with PS1. 
Furthermore, we did not find major differences in the subcellular localisation of APP 
and PS1 in TV1 and TV2 overexpressing cells. It is possible that these effects could be 
the result of ubiquilin-1 modulation of γ-secretase-interacting proteins. Further studies 
will be required to reveal the exact underlying mechanisms behind the effects of TV1 
and TV2 on γ-secretase modulation. 
 
Yet another important aspect to the γ-secretase modulation is the observed substrate 
competition between APP and LAR mediated by TV1. TV1 overexpression with APP or 
LAR resulted in increased ICD generation in both cases separately. However, when 
APP and LAR were combined, the γ-secretase preferred LAR over APP in the presence 
of TV1 overexpression, resulting in increased LICD, but not AICD, generation. 
Substrate competition is not new to the γ-secretase field, with substrate competition 
between substrates such as Notch1 or LRP and APP being reported (Lleo A. et al., 2003, 
Lleo A. et al., 2005, Berezovska O. et al., 2001). In our studies, we did not find any 
changes in the plasma membrane levels of APP ruling out altered APP trafficking as a 
possible explanation for the substrate competition. Instead, a more likely possibility is 
that TV1 directly modulates the γ-secretase resulting in substrate competition between 
APP and LAR. On the other hand, based on microscopy and surface biotinylation 
experiments, we know that the levels of APP on the plasma membrane are very low in 
SH-SY5Y-APP751 cells. In contrast the levels of LAR at the plasma membrane are 
highly abundant, as shown previously (Haapasalo A. et al., 2007). Since majority of the 
ICD generation takes place at or near the plasma membrane (Kaether C. et al., 2006b), it 
is possible that LICD levels are increased simply because there is more LAR available 
for γ-secretase cleavage at the plasma membrane compared to APP.  
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Figure 9. Schematic representation of the effects of TV1 and TV2 on APP processing and γ-
secretase activity. 1. Overexpression of TV1 and TV2 increases APP maturation in the 
secretory pathway. 2. APP processing is also increased, leading to increased C83 and C99 
levels and sAPPtot levels (3.). This is more pronounced in cells overexpressing TV1 
compared to TV2. The midline represents that the effects indicated by 4. and 5. likely take 
place through separate underlying mechanisms. 4. TV1 but not TV2 overexpression leads to 
increased AICD generation by the γ-secretase. However, when TV1 is overexpressed along 
with LAR, the AICD increase is abolished. Instead LICD generation is increased, suggesting 
substrate competition between APP and LAR in the presence of TV1 (5.). 
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7. Conclusions 
 
The aim of this thesis was to genetically and functionally characterise Alzheimer’s 
disease (AD)-related risk genes. We focused on the genetic contributions of APP gene 
locus duplications and GRN polymorphisms on AD, and the functional effects of 
ubiquilin-1 on PS1 accumulation, APP processing and γ-secretase function. Based on 
our findings, we can make the following conclusions: 
 
1. Duplications in APP have been reported in European and Asian EOAD populations. 
The extra copy of APP increases gene dose, leading to earlier onset of AD. However, 
our screen of Finnish EOAD patients revealed no duplications, suggesting that this is a 
rare genetic phenomenon in Eastern Finnish AD population. However, such studies 
and findings are important as they reveal a novel and uncommon mode of genetic 
inheritance of AD that is separate from that of the causative mutations. 
 
2. Polymorphisms in the GRN gene, which plays an important role in FTD, were found 
to be over-represented among male AD patients. This suggests that GRN can increase 
the susceptibility for AD. These findings suggest that interrelationships may exist 
between pathological mechanisms underlying dementias such as AD and FTD. 
 
3. Ubiquilin-1 TV1 and TV3 cause accumulation of PS1 into aggresomes. 
Overexpression of TV1 and PS1 may overwhelm the UPS capacity, leading to targeting 
of excess PS1 to aggresomes. TV3 induced aggresome formation was much more 
pronounced compared to TV1. We hypothesise that since TV3 lacks the majority of an 
essential domain required for proteasomal interaction, it is unable to efficiently target 
PS1 to the proteasome for degradation. As a result, PS1 accumulates and is targeted to 
aggresomes. Furthermore, we suggest that PS1-containing aggresomes are degraded via 
autophagy. This observation suggests that aggresome formation is a neuroprotective 
mechanism that is utilised to temporarily and safely store potentially harmful 
accumulated or aggregated proteins. These aggregates may then be gradually degraded 
via the autophagosomal/autolysosomal pathways. These findings provide further proof 
for the growing impression that protein aggregates in neurodegenerative diseases may 
be less neurotoxic than initially thought. 
 
4. Ubiquilin-1 TV1 increases APP processing and maturation and modulates especially 
the ε-cleavage by the γ-secretase. These effects appear to be mediated via independent 
mechanisms. TV2, which is genetically associated with AD, also increases APP 
processing, but to a lesser extent as compared to TV1. Furthermore, in contrast to TV1, 
TV2 does not alter γ-secretase activity. These differences could be the result of 
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structural differences caused by the splicing out of exon 8 in TV2. As TV2 mRNA levels 
have been shown to be increased in AD brains, the effects of TV2 on the key processes 
involved in the amyloid cascade or other neuropathological events will provide novel 
insights into the exact molecular mechanisms behind the role that TV2 plays in AD and 
neurodegeneration. 
 
In conclusion, the findings reported and discussed in this thesis shed new light on 
genetic phenomena as well as functional aspects of APP, GRN and ubiquilin-1 on AD 
pathogenesis. These studies further our knowledge and understanding of the 
underlying molecular mechanisms behind the pathogenesis of AD and may help to 
identify potential new targets for therapeutic interventions against AD.  
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